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ABSTRACT 
 The goal of the work undertaken in this dissertation was to understand the 
molecular mechanisms and develop translational findings for the use of Histone 
Deacetylase (HDAC) inhibitors as pharmacotherapy for patients with heart failure (HF). 
Efficacy of HDAC inhibitors in pre-clinical models of HF has been appreciated for 
several years, yet the molecular mechanisms by which these compounds exert beneficial 
effects on the heart remains incompletely understood. This may be due to the fact that 
HDACs and lysine acetylation are implicated in virtually every cellular process, not just 
their canonical function of regulating gene transcription. This dissertation describes the 
findings of cardiac lysine acetylation being inextricably linked to cardiac lysine 
modification by the Small Ubiquitin-like Modifier-1 (SUMO-1) in a way that was at first, 
counterintuitive, but is now consistent with several  independent studies of cardiac 
pathophysiology. Next, a new role for cardiac c-Jun Interacting Protein-1 (JIP-1) in 
cardiac myocytes is described, a role that occurs in the presence of HDAC inhibitors, and 
does not involve its canonical function of inhibiting activation of c-Jun N-terminal 
Kinase (JNK). Finally, to push forth the ever accumulating evidence for the use of HDAC 
inhibitors in various forms of heart disease, HDAC protein expression and HDAC 
catalytic activity were assessed in human heart samples for the first time, comparing right 
ventricular (RV) samples from control pediatric donor hearts to RV samples from the 




syndrome. These findings were then translated to a rodent model of pediatric right 
ventricular hypertrophy (RVH), with the hope that this animal model will not only serve 
as a valuable tool for developing HDAC inhibitors for use in pediatric heart disease, but 
for other potential small molecule or gene therapies as well. It is my hope that this 
dissertation adds value to the field of cardiac biology, in drug development for 
cardiovascular disease, and serves as a research tool for basic science and clinical 
cardiovascular researchers for years to come. 
 
The form and content of this abstract are approved. I recommend its publication. 
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INTRODUCTION: HEART FAILURE EPIDEMIOLOGY, CURRENT 
TREATMENT STRATEGIES AND MOLECULAR MECHANISMS 
Current State of Heart Failure 
 Heart Failure is an enormous public health issue and economic problem in the 
U.S. and across the world. Each year, various government agencies including: the 
American Heart Association (AHA), Centers for Disease Control and Prevention, 
National Institutes of Health and others compile the current statistics regarding 
cardiovascular disease in the Heart Disease and Stroke Statistical Update (1). As of 
January, 2015, 6 million adults in the U.S. have HF and this number is expected to jump 
to 8 million in 2030 (1). This increase in HF patients will have significant economic 
implications, with the estimated cost of HF in 2012 at $30.7 billion and is projected to 
increase to $69.7 billion by 2030 (2). At the forefront of combating these significant 
cardiac disease issues are the AHA’s 2020 Impact Goals, which focus on using evidence-
based approaches to more effectively treat HF patients by altering behaviors, improving 
data collection and outcomes research, improving patient surveillance following a 
cardiovascular disease event, and leveraging existing science to encourage additional 
research. These strategies are a great step toward improving cardiovascular outcomes, but 
improving a patient’s status with pre-existing HF still remains a monumental issue. 
 As basic science researchers, we pride ourselves on using existing research to 
guide us on a path toward developing better therapeutics for patients, as well as factoring 
in the crucial molecular and physiological mechanisms that will give us clues to finding 




signaling mechanism, patient symptom or pre-clinical observation is worth pursuing by 
basic science researchers to fight the increasing HF epidemic.  
Heart Failure Epidemiology 
 There are many different diseases of the heart that culminate in the final clinical 
stage of HF. HF is a complex clinical syndrome resulting from structural or systemically 
induced cardiac disorders that impairs the ability of the right or left ventricles to 
adequately fill or eject blood (3,4). These cardiac disorders cannot be summed up into a 
single diagnostic state. Many factors contribute to specific characteristics of HF 
including: age, sex, family history of disease, environment, genetic background, lifestyle 
and other co-morbidities. These underlying contributions to HF vary by patient and 
usually, with the exception of pediatric congenital heart diseases, take decades for 
symptoms to fully manifest. Several risk factors including: ischemic (coronary artery) 
heart disease, hypertension, smoking, diabetes and obesity, have been demonstrated to 
predict incidence of HF as well as the severity of the disease (5).  
Alarmingly, one in five individuals in the U.S. are at a lifetime risk for developing 
HF (6). This risk does not change even in patients over 80 facing a much shorter life 
expectancy (7). Though significant improvement in management of HF has occurred over 
the past several decades, data from the from the National Heart, Lung, and Blodd 
Institute’s (NHLBI) Atherosclerotic Risk in Communities study (ARIC) indicate that the 
30-day, 1-year, and 5-year mortality rates following initial diagnosis of HF were 10.4%, 
22% and 42.3% respectively (8). The age-adjusted incidence of HF appears to have 
plateaued, however, with 870,000 new cases of HF developing each year (8), this is likely 




It is not surprising that a standard diagnosis of HF is difficult to achieve 
considering the complexity of the disease. Clinical studies have used multiple diagnosis 
criteria to select patients for HF trials including criteria from: the Framingham Heart 
Study (9), Cardiovascular Heart Study (10), and the European Society of Cardiology 
(11). Careful consideration must be taken when comparing HF statistics from different 
studies, especially when estimating HF prevalence, incidence and associated mortality 
worldwide. One measurement that appears to be consistent between recent HF studies is 
that HF prevalence greatly increases with advancing age (1,12). Increasing incidence in 
HF among elderly populations is likely due to increasing trends in hypertension and 
ischemic heart disease among the elderly (13,14). Also, differing incidences of HF 
amongst white and black populations were attenuated when adjustment for 
atherosclerotic risk factors were taken into account, suggesting greater incidence of 
hypertension, diabetes and coronary artery disease may explain the differing incidences 
of HF among these populations (8). 
HF still has a 5-year mortality rate that is comparable to or worse than most 
cancers (5). Age and environmental factors may have an enormous impact on HF
mortality with 5-year mortality rates tallying 45-60% in Framingham, Massachusetts (6); 
75% after first hospitalization in Worcester, Massachusetts (15); and 41% in Rotterdam, 
Netherlands (16). These differences in percentages may be due to differences in patient 
selection and HF definitions. Another country to country difference lies in in-house 
mortality of HF. Data from HF in-patients deaths in the United States Medicare records 
decreased 4.2% between 1993 and 2006, from 8.5% to 4.3% in a patient population of 7 




hospital mortality did not change and remained high (>12%) from 1992-2000 (18). 
Holding these differences in mind, it is important to consider regional differences in 
healthcare, patient criteria selection, and definitions of HF when comparing statistics 
between national and international studies. Another factor to consider is that the recent 
improvements in HF mortality largely stem from male and younger patient populations. It 
is unclear why men have seen more improvement than women, but this could be 
explained by a greater prevalence of HF with Preserved Ejection Fraction (HFpEF), 
which is more common in females and for which no effective pharmacotherapy exists 
(19); current pharmacotherapies may be more effective in men than in women; men 
generally have a higher risk of HF and women may start with lower HF mortality (5). 
These data suggest that sex differences should also be taken into account when analyzing 
improvements in HF care and mortality. The AHA has found improvements in the last 
five years of HF mortality, from 1 in 8 US death certificates mentioning HF in 2010 (20) 
to 1 in 9 in 2015 (1); however, there is plenty of room for improving HF mortality. 
Perhaps the most important risk factor for HF is ischemic heart disease, with 1 in 
3 patients developing HF 7-8 years after an acute myocardial infarction (MI) (21). 
Hypertension also plays a major role in HF, with: 75% of HF cases having antecedent 
hypertension, and the lifetime risk for developing HF in patients with a blood pressure 
greater than 160/90 mmHg is double that of people with a blood pressure less than 
140/90 mmHg (7). Diabetes greatly increases risk of developing HF, 2-8 fold with risk 
ratios that are twice as high in women than in men (22). Dyslipidemia, or an excess 
amount of lipids like cholesterol and fats, increases the risk for atherosclerosis and a ratio 




(23). Both past and current cigarette smoking increase the risk of HF, where in past 
smokers there was a dose-effect association that was not found in current smokers (24). 
Obesity is also associated with and increased risk of HF, where a patient’s risk for 
developing HF increase 5% for men and 7% for women for every 1 unit of body-mass 
index (BMI) ratio (25). Optimal management of HF risk factors has and will likely 
continue to improve outcomes of complications deriving from HF. 
HFrEF vs. HFpEF 
 A common method for testing cardiac function non-invasively in the clinic is 
echocardiography, or taking an ultrasound of the chambers of the heart. Measurements 
from echocardiography can calculate the amount of blood pumped out of the left 
ventricle (LV) of the heart with each beat. This calculation is called ejection fraction 
(EF). Left ventricular ejection fraction (LVEF) of less than 40-45% is an average 
benchmark for diagnosis of systolic HF and/or inclusion into HF clinical trials (19,26-
28). Intuitively, one would think that if the heart cannot pump enough oxygenated blood 
to the rest of the body, the peripheral organs would shut down. This dysfunctional 
pumping action or systolic dysfunction of the heart would be categorized as HF with 
reduced Ejection Fraction (HFrEF). Currently, all of our pharmacological treatment 
strategies target HFrEF, including beta blockers, which paradoxically, do not directly 
signal the heart to contract more rapidly (29-31). Treatment of HFrEF has dramatically 
improved over the last several decades; however, HF with preserved ejection fraction 
HFpEF is now recognized as being responsible for over 50% of HF cases and does not 
have a proven effective management strategy (19,27,27,32). HFpEF occurs when after 




hypertrophy) as well as abnormal relaxation and filling (33). HFpEF is also known as 
diastolic HF. Intense basic research; clinical focus and therapeutic development are 
concentrating on HFpEF, as it remains one of the most debilitating diseases we face 
today.  
240 Years of HF Pharmacotherapy 
A ten year process of empirical observation resulted in William Withering’s 
publication describing the efficacy of using dried foxglove leaves for the treatment of 
dropsy in 1785 (34). Withering was a botanist as well as a physician with a vast 
knowledge of medicinal herbs stemming from his extensive documentation of the natural 
vegetation in Great Britain (35). In Withering’s time, dropsy was multi-faceted disease in 
which edema (hydrothorax) was present, secondary to congestive HF, along with other 
pathophysiologies, such as: liver disease, kidney disease, ovarian cysts, and potentially 
intra-abdominal cancers (36). Though there were many successes of treating dropsy 
patients with foxglove leaves, Withering documented potential toxicities as well. By his 
own account, efficacy of prescribed foxglove leaves occurred in about two-thirds of his 
patients. The active compounds in foxglove leaves (Digitalis purpurea) are known today 
as digoxin and digitoxin, and collectively referred to as digitalis.  
Withering was aware of the anti-arrhythmogenic effects of digitalis, stating that it 
had “a power over the motion of the heart, to a degree yet unobserved in any other 
medicine.” However, Withering primarily used digitalis as a diuretic, “one of which, 
though not infallible, I believe to be much more certain than any other [diuretic] in 
present use” (34,37). In an effort to quantify the efficacy of Withering’s treatment of 




retrospectively assessed the symptoms of Withering’s patients pre and post-digitalis 
prescription. Dr. Weisse found that the favorable effects of digitalis occurred in 64% of 
152 patients. When the patient population identified as most-likely to have HF were 
separated out, that number rose to 89% (36). This documented efficacy of digitalis for 
CHF patients is staggering even by today’s standards. Dr. Weisse correctly asserts that 
had Withering’s exact procedure and results been presented to a modern journal, they 
would have been immediately rejected. However, along with Edward Jenner’s 17λ6 
discovery of the smallpox vaccine, which by today’s standards was highly unethical, 
millions of patients over the past 200 plus years have benefitted from Withering’s 
discovery. 
In the 1950s, rapid digitalization (reaching optimal therapeutic concentrations of 
cardiac glycosides i.e. digoxin and digitoxin) was achieved using lanatoside-C 
(Cedilanid) administered intravenously (IV). Sources of digitalization were: digitoxin, 
digoxin, and digitalis leaf  (38). Digitoxin is completely absorbed by the gut, making a 
loading dose more feasible. However toxicity induced by digitoxin would be more 
prolonged than with digoxin. Only 50-80% of digoxin is absorbed, shorter lasting, 
patients may be underdigitalized by forgetting to take a dose, but would recover more 
quickly if toxicity occurred. Digitalis leaf was preferred by some physicians, because in 
the event of toxicity, patients would vomit the remaining digitalis leaf in the gut. 
Eventually, orally available Digoxin won out and its formulation is what is still used by 
cardiologists today. Digoxin use is on the decline in today’s cardiology clinic despite 
demonstrating the highest rates of success when combined with beta-blockers and/or 




(AFFIRM) studying AFib rate control at rest and at exercise (39). Another source to 
dwindling confidence came from the Digitalis Investigation Group, where 6,000 patients 
showed no difference in all-cause mortality when digitalis was added to other 
medications, despite reducing hospitalizations and the progression of HF (38). 
Deep gratitude should be held for William Withering’s work, not only for the 
innovations he achieved as a physician, botanist and pharmacologist, but for his 
unrelenting quest for scientific veracity. In his book detailing 163 reports of observations 
after the prescription of Foxglove, he included every case, regardless of therapeutic 
benefit or toxic consequence. He reasoned “it would have been an easy task to have given 
select cases, whose successful treatment would have spoken strongly in favor of the 
medicine, and perhaps been flattering to my own reputation. But Truth and Science 
would condemn the procedure (34).” This is truly a fitting mantra for today’s physicians 
and scientists around the world conducting responsible research. 
HF pharmacotherapy has come a long way since the advent of efficacious digitalis 
treatment for congestive HF. However, due to the lack of a proven therapy for HFpEF 
and for a variety of congenital heart diseases, we still have a long way to go. 
Current Pharmacotherapy for HF 
 Approximately 90% of HF care is delivered in outpatient facilities, while 80% of 
HF costs derive from inpatient facilities (2). Any effort to prevent hospitalization of HF is 
not only more beneficial for the patient, but has incredible implications for the overall 
economic burden of HF. Alongside a healthier lifestyle and diet, optimal 
pharmacotherapy for patients with, and who are on the path toward HF, is an impactful 




modifying therapies that reduce mortality also reduce LV volume, or reduce pathologic 
cardiac remodeling (40). Described below, are the current standards of HF 
pharmacotherapy, the cellular pathways they target, and clinical trial evidence for their 
use in patients. Patients are typically categorized using the New York Heart Association 
(NYHA) functional class system (Table 1(41)). 
 The Renin-Angiotensin-Aldosterone System (RAAS) is a crucial regulator of 
vascular hemodynamics and cellular signaling at the cardiac myocyte. The primary 
means of modulating the RAAS system is through the use of Angiotensin Converting 
Enzyme Inhibitors (ACEi). Listed in Table 2 are many ACEi that have shown efficacy in 
clinical trials. The first of which, was enalapril in the 1987 CONSENSUS trial that 
demonstrated efficacy in patients with NYHA function class IV, or severe HF. After 188 
days, overall mortality rate was decreased 27% (42). Importantly, these data were 
followed up by the SOLVD trial 4 years later where patients on enalapril saw a 16% 
reduction in mortality at 41 months and significant reduction in LV volume at 4 months 
(43). Other HF trials using ACE inhibitors include: the Survival and Ventricular 
Enlargement (SAVE) trial, using captopril (44); the Acute Infarction Ramipril Efficacy 
trial (45); and the Trandolapril Cardiac Evaluation trial (46). All of which demonstrated 
significant risk reduction in all-cause mortality versus placebo (40). The 
pharmacodynamic effects of ACE inhibitors are: inhibiting Angiotensin Converting 
Enzyme from processing angiotensin I to angiotensin II, and inhibiting the degradation of 
bradykinin. Excess angiotensin II can elicit pathophysiological effects on the vasculature 
and myocardium including: vasoconstriction, abnormal myocyte growth, sodium and 




Table 1: New York Heart Association classification system. Adapted from 41.  
 
angiotensin II in mice to promote cardiac fibrosis (48). The beneficial cardiovascular 
effects of ACE inhibition include: RAAS modulation at the level of the cardiac myocyte, 
improvement in ventricular function, reduced ventricular remodeling, reduced 
sympathetic activity, improved exercise capacity and arterial compliance (40). 
The advent of Angiotensin Receptor Blockers (ARBs) provided a new way to 
pharmacologically modulate the RAAS system. These agents are particularly 
advantageous when ACE inhibitors are not tolerated in patients and as an adjuvant to 
ACE inhibitors when -blockers are not tolerated (49). The best evidence for ARB 
efficacy in HF comes from the Valsartan in Acute Myocardial Infarction (VALIANT) 
study (50) and from the Candesartan in HF Assessment of Reduction in Mortality and 
Morbidity (CHARM) study (51). Data from the VALIANT study demonstrated that in 
patients with MI and suffering complications of HFrEF, patients receiving valsartan, 
captopril, or a combination of valsartan and captopril demonstrated no significant 




Table 2: Current pharmacotherapy standards for heart failure. Indicated doses are for 
late-stage heart failure. *Agent is still being compared to warfarin. B.i.d. (b s in die, twice 
daily), t.i.d. (ter in die, three times daily), q.d. (quater in die, four times daily). Table was 
adapted from and extended from 40, 49. 
 
arms (50). The CHARM-Alternative study was exceptionally designed to bring ARB HF 
therapy to the clinic in an evidence-based manner. Patients in the NYHA class II-IV 
range for HF, with an LVEF <40% and who were not taking an ACE inhibitor due to 
previous intolerance were enrolled and randomized to candesartan and placebo treatment 
groups. The primary combined end point risk reduction was 23% after about 34 months 




includes a more complete blockade of the deleterious effects of angiotensin II by 
blocking the angiotensin receptor and circumventing ACE inhibitors in situations where 
angiotensin II is generated through non-ACE pathways (53).    
 Addition of Mineralocorticoid Receptor Antagonists (MRAs) also known as 
aldosterone antagonists has been demonstrated to improve HF outcomes in the presence 
of other gold standard therapies. The Randomized Aldactone Evaluation Study (RALES) 
trial investigated the use of spironolactone compared to current standards of care in 
patients with NYHA class III or class IV HF with an LVEF of <35%. All patients 
received an ACEi and a loop diuretic. After a mean follow-up of 2 years, the trial was 
stopped early due to clear benefit in the spironolactone + ACEi + loop diuretic treatment 
arm, with a 30% risk reduction in all cause mortality (54). The Eplerenone Post-Acute 
Myocardial Infarction HF Efficacy and Survival (EPHESUS) trial demonstrated efficacy 
of MRAs in a different patient population than the RALES trial. The EPHESUS 
investigators examined whether the MRA eplerenone would be effective in a patient 
population after acute MI and with an LVEF of <40%, on top of therapy where the 
majority of patients were taking an ACEi or ARB and a -blocker. After 16 months there 
was a 15% relative risk reduction in all-cause mortality in the eplerenone + ACEi or ARB 
+ -blocker arm (55). MRAs work to inhibit the effects of aldosterone, but their precise 
mechanism of action for why MRAs work in treating HF remains elusive (40). 
Downstream aldosterone signaling is associated with increased matrix metalloproteinase 
levels and promotion of cardiac fibrosis (56). Circulating levels of aldosterone are 




ARBs (57). Also, MRAs improve vascular endothelial function (58), attenuate LV 
remodeling and reduce LV volume (59,60).    
 Use of -adrenergic receptor blockers (-blockers) for treating systolic HF was 
initially counterintuitive because one would think that increasing the heart rate of a 
dysfunctionally pumping heart would be advantageous while attempting to pump 
oxygenated blood throughout the body. -blockers do the opposite by shielding, 
predominantly, the 1-adrenergic receptor from eliciting downstream signaling that 
results in calcium-induced calcium release (CICR) in cardiac myocytes and subsequent 
contraction. Now there is a rich literature of efficacious studies using -blockers to treat 
HF. The US Carvedilol HF Program (USCP) reached an astounding 65% reduction in all-
cause mortality in patients with LVEF <35% when carvedilol was used in addition to an 
ACEi (61). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) trial investigated 
whether the -blocker bisoprolol would be effective in patients with NYHA class III or 
class IV HF and with an LVEF <35%, the vast majority of which were on an ACEi. After 
around 16 months, the trial was discontinued due to clear efficacy, with a 34% relative 
risk reduction in all-cause mortality favoring the bisoprolol + ACEi treatment arm (62). 
Another efficacious -blocker trial with a different -blocker was the Metoprolol CR/XL 
Randomized Intervention Trial in Chronic HF (MERIT-HF). Patients with NYHA class 
II -class IV HF and an LVEF <40% demonstrated a 31% reduction in total mortality or 
hospitalizations because of worsening HF when metoprolol was added to ACEi (63). The 
adrenergic system and downstream signaling in the failing myocardium is desensitized to 
neurohumoral stimuli. A few explanations for the efficacy of -blockers are: repressing 




signaling in the myocardium, repression of heart rate, mild vasodilatation, potentiation of 
nitric oxide, re-sensitization of the myocardial adrenergic system and hence reversing 
abnormal adrenergic signaling resulting from chronic catecholamine stimulation (31,64).   
 Of the recently approved, though not yet commonly used agents for treating HF, 
Ivabradine was developed to target patient populations that remain symptomatic with 
high heart rates, despite being on optimal -blocker therapy. The evidence basis for use 
of Ivabradine in HF came from the Systolic HF Treatment With the If Inhibitor 
Ivabradine Trial (SHIFT) study, for which efficacy was assessed in patients with an 
LVEF <35% and a sinus rhythm with heart rate >70 beats per minute. As above, the vast 
majority of patients enrolled in the SHIFT trial were on ACEi or ARBs and -blockers. 
Results following patients at an average 23 months after initiation of the trial revealed an 
18% relative risk reduction of cardiovascular death or hospital admission for worsening 
HF (65). Ivabradine is a selective inhibitor of the If pacemaker current, which 
consequently slows diastolic depolarization in the sinus node without influencing other 
cardiac ion channels or altering other hemodynamic parameters (66). Interestingly, 
ivabradine is more effective when heart rate is higher, with minimal effects in patients 
with a low heart rate (66).   
 Perhaps the most ground breaking clinical trial for a new HF therapeutic in the 
last 25 years was the Prospective Comparison of ARNi With ACEi to Determine Impact 
on Global Mortality and Morbidity in HF (PARADIGM-HF) trial. In this trial, a fusion 
molecule of the ARB valsartan and a neprilysin inhibitor sacubitril, also known as 
LCZ696 was assessed for efficacy in a patient population with NYHA class II - class IV 




of LCZ696 over enalapril, the PARADIGM-HF trial was concluded early at 27 months 
with a 20% relative risk reduction in death from cardiovascular causes or hospitalization 
for worsening HF (67). By combining the effects of blockade of angiotensin receptors 
and inhibiting neprilysin, LCZ696 is thought to work by enhancing the beneficial effects 
of natriuretic peptides while concurrently inhibiting deleterious effects of a stimulated 
RAAS system (68).   
 As aforementioned, HF is a complex disease manifesting from potentially many 
factors, and as such, is difficult to standardize HF pharmacotherapy. However, the best 
resource for HF pharmacotherapy standards is the 2013 ACCF/AHA HF Guideline (49). 
Standards of care are classified by Size of Treatment Effect (Class I – Class III) and by 
Estimate of Certainty (Precision) of Treatment Effect (Level A-C) also described as 
Level of Evidence (LOE). For patients with HFrEF, the designated Class I and LOE A 
pharmacotherapy are an ACEi or ARB and a -blocker. Additional pharmacotherapy is 
recommended if patients have certain symptoms. For example: if a patient with HFrEF at 
NYHA class II-IV has chronic volume overload, a loop diuretic should be added. For 
persistently symptomatic African-Americans at NYHA class III-IV, hydral-nitrates 
should be added. For patients at NYHA class II-IV with estimated creatinine >30 mL/min 
and K+ <5.0 mEq/dL, an aldosterone antagonist should be added (49). With FDA 
approval of Ivabradine in April of 2015 and an expected approval of LCZ696 in August 
of 2015, it will be interesting to see how Ivabradine and LCZ696 are incorporated into 




Pediatric Heart Disease 
 Equally as large of an enigma as to how to treat HFpEF patients is how to treat 
pediatric HF patients. Children with HF are prescribed similar treatment regiments to 
their adult HF counterparts, however these treatments are not associated with improved 
outcomes in pediatric HF (69). Furthermore, there has only been one multicenter 
randomized-controlled clinical trial for pediatric HF, known as the Pediatric Carvedilol 
Trial (70). Unfortunately, results of the trial demonstrated no clear benefit for use of the 
non-selective –blocker, carvedilol in pediatric HF patients. Continuing this trend, two 
independent retrospective studies found no evidence of improvement in pediatric HF 
options from the digoxin/diuretics treatment strategy of the 1980s (71) and the current 
ACEi/ –blocker treatment strategy (72). However, pediatric cardiologists still prescribe 
ACEi and/or –blockers for pediatric HF because these drugs demonstrate no harm 
(69,73). These findings underscore the need for better HF pharmacotherapeutics and 
rationalize allocating basic research efforts to this cause. 
 The World Health Organization (WHO) classifies cardiomyopathies as: dilated 
Cardiomyopathy (DCM), hypertrophic Cardiomyopathy, restrictive Cardiomyopathy, or 
arrhythmogenic right-ventricular dysplasia Cardiomyopathy (74). HF symptoms from the 
majority of HF patients fall into one of these four categories filling strict diagnostic 
criteria, with few having mixed forms of Cardiomyopathy. However, the demographics 
providing clues for the underlying causes of these diseases are poorly characterized, 
especially in children (72). DCM resulting from the myriad of complications from 
pediatric HF for children under 18 years of age were tallied at 0.57 cases per 100,000 per 




 Several congenital lesions can result in the WHO’s listed classifications of HF. 
Myocarditis and pericarditis typically caused by viral or autoimmune disorders are 
inflammatory conditions of the heart. Myocarditis ranges from displaying flu-like 
symptoms to overt HF, while pericarditis symptoms usually involve chest pain and fever 
(75). Tetralogy of Fallot (ToF) is the most common cyanotic (blue lips and skin) 
congenital heart disease that is characterized by four developmental abnormalities of the 
myocardium. These abnormalities include: 1) ventricular septal defect, 2) over-riding of 
the aorta, 3) right ventricular outflow obstruction, and 4) right ventricular hypertrophy 
(76). Surgical palliation of these dysfunctional cardiac parameters has allowed the 
majority ToF patients to survive into adulthood. The congenital malformations displacing 
the basal insertions of the septal and posterior leaflets of the tricuspid valve, known as 
Ebstein’s anomaly, can lead to cyanosis for neonates, HF for children, incidental murmur 
for children, and arrhythmia in adolescents and adults (77,78). Though classification is 
standard for the congenital heart defects described above, the majority of pediatric HF 
patients suffer from an unknown cause or Idiopathic Dilated Cardiomyopathy (IDC), 
making IDC the most common diagnosis in pediatric HF populations (72).  
Work later described in this dissertation focuses on a single ventricle (SV) 
congenital heart defect known as Hypoplastic Left Heart Syndrome (HLHS). HLHS is 
characterized by an underdeveloped LV and LV components that are unable to perform 
systemic circulation, and is uniformly fatal without surgical intervention (79). Surgical 
palliation of the hypoplast SV heart includes three distinct surgeries at different stages of 
life that are summarized in Table 3. Though HLHS is uncommon, if surgical palliation 




After the surgeries are complete, HLHS patients utilize the right ventricle for systemic 
and pulmonary circulation. This added pressure on the right ventricle often leads to right-
sided HF later in life. Currently, no genetic marker has been identified as specific for 
HLHS, and there is no proven pharmacotherapy for HLHS. Effective drug regimen(s) to 
improve quality of life for this patient population would likely delay the need for  
Table 3: Surgical palliation stagest for HLHS patients. SataO2 = typical arterial oxygen 
saturation level after this procedure. Adapted from 80.  
 
transplant, which would be an incredible advantage for patient longevity, as the current 
half-life of a transplanted heart is around 10 years (81). 
Despite the rarity of pediatric heart disease, continuing efforts exist to remedy the 
lack of a proven therapeutic in this population. The highest Level of Evidence (LOE) 
therapy recommended by the International Society for Heart and Lung Transplantation 
Guidelines for the management of HF is at LOE B (73). These drugs include ACEi and 
–blockers, while mineralocorticoid antagonists, ARBs, digoxin, diuretics, anti-




efficacy scale. Recent efficacy for 1–AR selective blockade was demonstrated in a 
pediatric model of cardiac hypertrophy (69). This question of whether 1–AR selective 
(metoprolol) vs. 1, 2, 3–AR selective (carvedilol) –blockers was attempted in the adult 
2003 Carvedilol Or Metoprolol European Trial (COMET) (82). Results from the study 
claimed that carvedilol reduced all-cause mortality over metoprolol after a 4.5 year 
follow up. However, there has been much controversy over the results of this trial, as half 
of the maximum daily use of metoprolol (100mg/day) was used versus the full maximum 
daily dose of carvedilol (25mg/day), potentially yielding an unfair advantage for 
carvedilol (83). Despite this debate remaining unresolved for adult HF (84), the fact that 
1–AR selective treatment demonstrated efficacy in a pediatric murine model of cardiac 
dysfunction holds exciting implications for further development in pediatric populations.  
Molecular Mechanisms of Cardiac Hypertrophy 
 Just as complex as the manifestations of HF are the molecular signaling pathways 
that occur during HF pathogenesis. Cardiac hypertrophy will be defined in this 
dissertation as pathological growth of cardiac myocytes. Cardiac hypertrophy is thought 
to be a compensatory mechanism occurring to adapt the myocardium to increased 
ventricular wall stress. However, chronic cardiac hypertrophy is thought to lead to 
cardiac dysfunction if this compensation is not alleviated in a timely manner. This 
chronic cardiac hypertrophy can be caused by aberrant neurohumoral activation, 
hypertension and myocardial injury from ischemic events (85). Hypertrophic growth of 
individual myocytes is a by-product of increased protein synthesis and enhanced 
organization and size of the force generating substructures of the myocyte (cardiac 




gold-standard pressure overload cardiac hypertrophy animal model termed transverse 
aortic constriction (TAC), where a band is tied around the aorta of the mouse, cardiac 
mass increases significantly in a matter of days. Conversely, when TAC is reversed and 
hemodynamic unloading occurs cardiac mass can decrease 25% in one week (88,89). Due 
to prolonged cardiac hypertrophy being an independent predictor of morbidity and 
mortality (90), especially in patients with HFpEF (91), investigation into intracellular 
signaling pathways governing myocyte hypertrophy is an intense area of research focus, 
with the hope of finding more druggable targets to treat HF. 
Induction of intracellular signaling cascades that trigger myocyte hypertrophy 
occurs in response to biomechanical stress and neurohumoral factors (85). The precise 
molecular mechanisms of how biomechanical stress triggers hypertrophic growth are 
incompletely understood, but likely involve stretch-sensitive ion channels, integrins, and 
structural proteins that connect the extracellular matrix, intercellular cytoskeleton and 
components of the sarcomere (92). Neurohumoral factors that act in paracrine and 
autocrine fashions include: angiotensin II, endothelin-1 (ET-1), epinephrine, and 
norepinephrine (NE). Interestingly, mechanical stretch of cardiac myocytes can activate 
angiotensin II receptors directly in a manner independent of angiotensin II ligand (93).  
Activation of downstream hypertrophic molecular signaling can occur through 
cell surface receptors termed G-protein coupled receptors (GPCRs). Pertinent to their 
name, GPCRs are coupled to small G-proteins on the cytosolic side of the plasma 
membrane that elicit downstream signaling upon ligand binding to the GPCR. 
Angiotensin-II, endothelin-I and –adrenergic receptor activating catecholamines that 




phospholipase C (PLC ). PLC  processes diacylglycerol (DAG) at the plasma 
membrane, which binds and activates to protein kinase C (PKC) leading to the production 
of inositol-1, 4, 5-triphosphate (IP3). IP3 binds to IP3 receptors at the sarco/endoplasmic 
reticulum or the nuclear envelope, leading to a mobilization of internal Ca2+ (94). This IP3-
mediated influx of Ca2+ from subcellular stores can mediate hypertrophic signaling 
through activation of the calcineurin (CaN)-nuclear factor of activated T cells 
(NFAT)(95) or through inactivation of calmodulin dependent kinase (CaMK)-HDAC 
signaling (96). There are several endogenous inhibitors of NFAT transcriptional activity. 
The kinases: glycogen synthase kinase-3 (GSK3 ) (97), p38 (98) and c-Jun N-terminal 
Kinase (JNK) (99) phosphorylate NFAT in cardiac myocytes leading to sequestration of 
NFAT in the cytoplasm and subsequent inactivation of NFAT transcriptional activity. 
Also, modulatory calcineurin-interacting protein (MCIP) acts as a CaN inhibitory protein 
when overexpressed (100). MCIP, also known as RCAN1, protein expression is a useful 
biomarker for detecting cardiac remodeling  vivo (101).    
 CaN is a Ca2+-dependent serine/threonine phosphatase that is a pivotal pro-
hypertrophic signaling molecule (102). CaN is a dimer with a 57-61 kDa catalytic subunit 
(CaN-A) and a 19 kDa regulatory subunit (CaN-B). The CaN dimer is activated when 
saturated with Ca2+, allowing CaN to bind to NFAT transcription factors. Once CaN 
binds to NFAT, it dephosphorylates specific N-terminal serine residues resulting in 
NFAT translocation to the nucleus and activation of pro-hypertrophic genes (95). The 
NFAT family of transcription factors has been shown to be both necessary (knockout 





 Increased cytosolic Ca2+ also has implications in the hypertrophic signaling 
pathway involving: CaMK, Class IIa HDACs and myocyte enhancer factor-2 (MEF2). 
IP3 directly activates local CaMK to phosphorylate HDAC5 and facilitate its 
translocation to the cytoplasm (96). Class IIa HDACs harbor MEF2 binding sites, of 
which the binding interaction between class IIa HDACs and MEF2 inhibit MEF2’s 
ability to activate genes involved in muscle growth (104). The roles of various HDAC 
isoforms in the heart will be more extensively discussed in subsequent sections. 
 A hallmark of cardiac hypertrophy is increased protein synthesis. Signaling 
through AKT/PKB has been demonstrated to activate protein synthesis by activating the 
mammalian target of rapamycin (mTOR) (105). Pertinent to its name, inhibition of 
mTOR by rapamycin can reverse myocardial dysfunction and attenuate cardiac 
hypertrophy (106,107). mTOR regulates protein synthesis by activating p70/85 S6 
kinase-1 (S6K1) and p54/56 (S6K2), and hence increasing ribosomal biosynthesis 
leading to increased protein translation; as well as releasing 4E-binding protein-1 from 
eIF4E, leading eIF4E to bind to other initiation factors and increase protein translation 
(105,108).  
 Though the molecular mechanisms of cardiac hypertrophy are vast and complex, 
identification of druggable targets has not been ideally fruitful. Fortunately, new 
signaling pathways that play critical roles in cardiac hypertrophy are being discovered 
and are yielding new drug targets. A simultaneous discovery by our lab and another 
indicated efficacy of the bromodomain and extra-terminal domain (BET) inhibitor JQ-1 
in blunting pressure-overload hypertrophy, indicating a role for BET proteins in cardiac 




ubiquitin-like modifier-1 (SUMO-1) demonstrated protective effects in pressure-overload 
hypertrophy, while conversely, short-hairpin RNA (shRNA) mediated knockdown of 
SUMO-1 was detrimental for cardiac homeostasis in unstressed mice (111). Hopefully in 
the near future, pharmacological and genetic therapies such as these and others will show 
promise for the 50% of HF patients whose HFpEF affliction has no proven therapy. 
Cardiac Fibrosis 
 Another inherent hallmark of HF is cardiac fibrosis, which occurs when 
pathophysiological stresses spanning myocardial infarction, hypertension, 
atherosclerosis, hereditary and toxin-related cardiomyopathy (112). After MI, the local 
hypoxic myocardial insult typically results in a loss of cardiac myocytes by apoptosis or 
necrosis, proliferation of cardiac fibroblasts, and an increased deposition of extracellular 
matrix (ECM) proteins. This excessive filling of the myocyte void by interstitial fibrosis 
is thought to be an initial adaptive process to allow the ventricular wall to cope with the 
loss of local myocytes and adapt to ventricular wall stress. However, prolonged fibrosis 
will eventually lead to ventricular dilatation and systolic dysfunction. Due to the wide 
range in the presence of cardiac fibrosis stemming from various causes of cardiac 
dysfunction as well as the absence of proven therapies to treat cardiac fibrosis, molecular 
mechanisms targeted at understanding the causation and potential pharmacotherapeutic 
manipulation of the fibrotic cellular signaling pathways are attractive areas of ongoing 
research. 
A large focus targeting cardiac fibrosis disease pathology derives from the cardiac 
fibroblast. Though the cardiac myocyte is the primary contractile unit of the heart, the 




the majority of these non-myocytes being cardiac fibroblasts (113). Cardiac fibroblasts 
have long been defined as mesenchymal derived cells that are phenotypically distinct 
from cardiac myocytes and capable of producing ECM components like collagen, 
fibronectin, vimentin, periostin and 1-integrin (114,115). These ECM components are 
highly expressed in cardiac fibroblasts, but are not specific to cardiac fibroblasts 
(116,117). Adding to the complexity of the roles of cardiac fibroblasts in cardiac growth, 
function and cellular crosstalk is the ever-accumulating evidence of the roles of 
subpopulations of cardiac fibroblasts. These subpopulations have their own functional 
RAAS system (118), as well as play roles in cardiac electromechanical coupling 
(119,120), cardiac and ECM remodeling (121), and autocrine and paracrine signaling 
(122). 
The subpopulation of cardiac fibroblast of particular interest for drug 
development is the myofibroblast, due to its implications in pathological cardiac fibrosis. 
Myofibroblasts differentiate from cardiac fibroblasts and confer a more “active” 
phenotype, due to their involvement in mechanical contraction and tissue remodeling 
(123). This “activation” is triggered by a variety of cellular stresses as well as 
extracellular signaling molecules, such as: transforming growth factor  (TGF- ) (124), 
interleukin-18 (IL-18) (125), and platelet derived growth factor D (PDGF-D) (126). A 
major differential biomarker of whether a fibroblast has differentiated into a 
myofibroblast is the presence of –Smooth Muscle Actin (SMA) (123). Careful 
consideration should be taken when studying characteristics of cardiac fibroblasts and 
cardiac myofibroblasts in cell culture because SMA expression increases after every 




myofibroblast phenotype (112). Importantly, with the exception of in valve leaflets, 
myofibroblasts are never found in the normal heart, but are prevalent and persistent after 
cardiac injury (127). As such, pharmacological targeting of cardiac fibrosis is an area of 
intense research interest. Our lab and others have demonstrated the beneficial effects of 
HDAC inhibitors on cardiac fibrosis in various animal models (48,128-130). Also, recent 
evidence shows that cardiac fibroblasts can be reprogrammed into cardiac myocytes by 
expressing a combination of GATA4, HAND2, MEF2C and TBX5 (131,132). It will be 
interesting to see if these methods develop into therapeutic approaches to treat cardiac 
fibrosis in the future.  
Histone Deacetylases (HDACs) 
 The enzymes that are the primary focus of this dissertation are histone 
deacetylases (HDACs), which are classically known for their involvement in epigenetics. 
Epigenetics is the study of changes in DNA expression from factors that are not encoded 
in the genome. At the level of chromatin, DNA is wrapped around an octamer of proteins 
known as histones forming an individual nucleosome that resembles a “hairy hockey 
puck”. These protruding “hairs” are N-terminal histone tails that play host to many 
different post-translational modifications (PTM), which influence gene expression at the 
specific modification locus in the genome. Of these PTMs, histone acetylation at the ε–
amino groups of lysine residues is among the most widely studied. Acetyl moieties are 
transferred to, or written on lysine residues by histone acetyltransferases (HATs) and 
removed, or erased from lysine by histone deacetylases (HDACs). Acetylation of lysine 
is also “read” by proteins containing bromodomains, such as the bromodomains and 




readers (BET) and erasers (HDACs) demonstrate exquisite intercommunication of this 
PTM from three distinct families of enzymes to signal cellular actions at the molecular 
level (133-135). 
 There are 18 mammalian HDACs each encoded by their own gene and are 
divided into four classes based on sequence homology to yeast orthologs and by 
functional similarities: class I (HDAC1, 2, 3, 8), class IIa (HDAC4, 5, 7, 9), class IIb 
(HDAC6 &10), class III (SirT1-7), and class IV (HDAC11) (136). Class III HDACs, also 
known as sirtuins (SirT), require nicotinamide adenine dinucleotide (NAD+) as a catalytic 
cofactor, while class I, II and IV HDACs require zinc (Zn2+) as a catalytic cofactor. The 
mechanism of action of many HDAC inhibitors, including the small molecule HDAC 
inhibitors used in our lab, is through chelating Zn2+ in the active site. Therefore, this 
dissertation will focus primarily on Zn2+-dependent HDACs.  
 Class I HDACs serve epigenetic roles as components of large multi-protein 
complexes to influence chromatin architecture such as: Sin3, NuRD, CoREST and 
SMRT/NCoR (137,138). These large complexes are recruited to specific gene regulation 
sites by transcription factors with DNA binding domains that selectively target certain 
sequences of DNA. HDAC1 and HDAC2 are typically present in the Sin3, NuRD and 
CoREST complexes, while HDAC3 typically resides with the NCoR/SMRT complex. 
Though much emphasis on the functionality of HDAC1-3 is placed on the ability to 
regulate gene expression, it is important to mention that these HDACs likely serve many 
other non-genomic roles in the heart due to the discovery of thousands of lysine 




 Genetic knockout studies of individual HDAC isoforms have shed light on HDAC 
functionality in the heart. A common strategy for making cardiac specific deletions of 
genes is through CRE-recombinase driven by the –myosin heavy chain (MHC) 
promoter, to excise floxed alleles of a gene of interest. MHC is exclusively expressed in 
the cardiac myocyte, making gene manipulations driven by this promoter specific to 
cardiac muscle. Interestingly, conditional cardiac specific deletions of HDAC1 or 
HDAC2 result in no obvious phenotype, while concomitant homozygous loss of HDAC1 
and HDAC2 results in dilated Cardiomyopathy and cardiac arrhythmia prior to birth 
(143). Functional redundancy between HDAC1 and HDAC2 in the adult heart may occur, 
due to HDAC1 or HDAC2 conditional knockout mice being susceptible to isoproterenol 
or pressure overload-induced cardiac hypertrophy. In contrast to single cardiac-specific 
deletion of HDAC1 or HDAC2, deletion of HDAC3 in the neonatal heart is cause for 
serious metabolic turmoil, resulting in: overwhelming cardiac hypertrophy and elevated 
myocardial lipid accumulation due to gene expression driven by a constitutively active 
peroxisome proliferator-activated receptor (PPAR) (144).  Conversely, when HDAC3 
was deleted from the mouse heart and skeletal muscle later in development, severe 
cardiomyopathy and decrease expression of genes involved in lipid metabolism did not 
occur until the animals were fed a high fat diet (145). These data highlight the importance 
of HDAC3 in cardiac lipid metabolism.  
As briefly mentioned above, class IIa HDACs (-4, -5, -7, and -9) are well 
characterized as suppressors of cardiac hypertrophy (146), particularly HDAC5 and 
HDAC9 (147,148). Class IIa HDACs have an N-terminal, ~500 amino acid protrusion 




sequestering MEF2 from binding to promoters of pro-hypertrophic genes. Various 
hypertrophic stimuli lead to phosphorylation of the N-terminus of class IIa HDACs by 
kinases, such as PKC, PKD and CaMKII (149,150). This phosphorylation leads to 
nuclear export of class IIa HDACs, allowing MEF2 to bind to its target pro-hypertrophic 
gene promoters and activate transcription. Consequently, the C-terminal catalytic 
deacetylase domain of class IIa HDACs is under further investigation, due to the inability 
to deacetylate histones. Our lab and others have only been able to detect class IIa HDAC 
catalytic activity using an artificial substrate, the conformation of which does not exist in 
nature (151-153). It will be interesting to see if an endogenous substrate for class IIa 
HDAC catalytic activity is discovered in the next few years. 
 The class IIb HDAC6 is building focused research momentum for its roles in HF. 
Though HDAC6 has been shown to enter the nucleus, it primarily resides in the 
cytoplasmic compartment of the cell (154). The gold standard substrate and useful 
pharmacodynamic marker for HDAC6 catalytic activity is the acetylation status of –
tubulin (155). However, there are other clear acetylated substrates of HDAC6, such as 
heat shock protein 90 and cortactin (156). The roles of HDAC6 in the heart are beginning 
to be elucidated. HDAC6 was demonstrated to contribute to structural and electrical 
remodeling of atrial myocytes, and was suggested to trigger atrial fibrillation through 
tubulin deacetylation and disruption of microtubule networks in a dog pacing model 
(157). Our lab demonstrated that HDAC6-knockout mice were protected from LV 
systolic dysfunction in mouse models of TAC and chronic angiotensin II infusion (158). 
The absence of HDAC6 did not block cardiomyocyte hypertrophy or fibrosis, but cardiac 




have a role in desmin related Cardiomyopathy, in which a mutation in the chaperone 
protein B-crystallin (R120G) in murine hearts leads to accumulation of misfolded 
protein aggregates, triggering pathological cardiac remodeling and HF (159). In this 
model, hyperacetylation of tubulin, consequent of siRNA-mediated knockdown of 
HDAC6, is adaptive in the heart by promoting autophagic flux (160). 
 The roles of HDAC8, HDAC10, and HDAC11 in the heart are currently 
unknown. Catalytic activity of HDAC8 in the heart was shown to be elevated in a chronic 
DOCA-induced rat model of hypertension (161). The recent advent of HDAC8 specific 
small molecule inhibitors will be invaluable tools for determining the role of HDAC8 in 
the normal and diseased heart (162). HDAC10 is categorized as a class IIb HDAC due to 
its sequence homology to HDAC6. Interestingly, our lab discovered that knockdown of 
HDAC10 in cultured cardiac myocytes led to an increase in HDAC6 protein levels, 
suggesting that HDAC10 and HDAC6 may serve functionally redundant roles in the heart 
(153). HDAC11 is the lone class IV HDAC due to lack of sequence homology among 
other HDAC classes. Northern blot analysis in the original characterization of HDAC11 
revealed that HDAC11 is expressed in human hearts (163), yet a discernible function for 
HDAC11 in the heart has yet to be elucidated. 
 Aside from genomic role of HDACs in the heart, many more lysine acetylation 
PTMs have been identified in human cells and cardiac tissue by high throughput 
proteomics (141,164). These datasets have the potential to serve as invaluable tools to 
point basic cardiovascular researchers in a direction toward defining the roles of site-
specific lysine acetylation on target proteins. Two different site-specific lysine 




Like Modifier (SUMO). In neurons, a family member of MEF2 (MEF2A) promotes 
dendritic claw differentiation when SUMOylated at lysine-403. Consequently, Ca2+-
induced activation of CaN dephosphorylates MEF2A at serine-408 inducing a switch 
from SUMOylation to acetylation at lysine-403, leading to inhibition of dendritic claw 
differentiation (165). Additionally, the tumor suppressor Hypermethylated In Cancer-1 
(HIC1) is SUMOylated on lysine-314. Mutation of this lysine-314 to arginine, rendering 
this site unable to be SUMOylated significantly reduces its transcriptional repression 
potential. Lysine-314 was also found to be acetylated, and knockdown of SIRT1 
promoted HIC1’s SUMOylation (166). It is highly probable that functional consequences 
in the heart exist for site-specific lysine modification, and knowledge of specific lysine 
acetylation sites and crosstalk with other PTMs will contribute to new discoveries in this 
field. 
HDAC Inhibitors 
 Since the approval from the Food and Drug Administration (FDA) of two HDAC 
inhibitors, suberoylanilide hydroxamic acid (SAHA, vorinostat) and FK-228 
(romidepsin), to treat cutaneous T-cell lymphoma, great efforts have been undertaken to 
use HDAC inhibitors as drugs to treat a variety of other diseases 
(https://clinicaltrials.gov/ct2/results?term=histone+deacetylase+inhibitor&Search=Search
). Our lab and others have demonstrated HDAC inhibitor efficacy in various pre-clinical 
models of HF (146). The pan-HDAC inhibitor, Trichostatin A, has shown efficacy in 
TAC (167), MI, angiotensin II (167) and isoproterenol (ISO) (168) infusion pre-clinical 
models of HF. One of the FDA approved HDAC inhibitors, SAHA, demonstrated 




Though selective targeting of class I HDACs for the treatment of pathological cardiac 
hypertrophy still warrants further investigation, it is clear that inhibition of class I 
HDACs is beneficial in treating cardiac pathophysiologies. Our lab demonstrated that the 
class I HDAC inhibitor Mocetinostat (MGCD0103) as well as the class I HDAC inhibitor 
MS-275, blocked adverse cardiac signaling events in a rat model of RV hypertrophy 
(169). Our lab also demonstrated efficacy for Mocetinostat in a mouse model of cardiac 
fibrosis in response to angiotensin II infusion (48). Importantly, Mocetinostat improved 
cardiac function in a model of pre-existing cardiac dysfunction post-MI, which holds 
significant translational implications (170). A structurally similar HDAC inhibitor called 
PD-106 was also administered post-MI and demonstrated significant reduction in LV 
remodeling and improved cardiac function (171). A structurally distinct class I HDAC 
inhibitor that is a derivative of the fungal metabolite apicidin (API-D) partially blunted 
pathological cardiac hypertrophy induced by TAC and prolonged cardiac function up to 8 
weeks post-TAC (172). The weak, but selective inhibitor of class I HDACs, valproic acid 
(VPA), was demonstrated to block cardiac hypertrophy in various rodent models 
(130,167,173).  Taken together, a variety of HDAC inhibitors have demonstrated efficacy 
in pre-clinical models of HF. 
 As mentioned above, an endogenous substrate for class IIa HDAC catalytic 
activity remains elusive. However, the recent advent of highly selective class IIa HDAC 
inhibitors may serve as critical tool for discovering unidentified class IIa HDAC 
substrates (174). Class IIb HDAC inhibitors, tubacin and Tubastatin A have been well 
defined as selective HDAC6 inhibitors (175). Consistent with HDAC6 knockout mice, 




mouse models of TAC and chronic angiotensin II infusion (176). Also consistent with 
HDAC6 depletion, Tubastatin A decreased aggregate formation in cardiac myocytes 
expressing mutant B-crystallin (R120G) in a similar manner as siRNA knockdown of 
HDAC6 (177). 
The HDAC inhibitors described above have divergent structures. There are short 
chain fatty acids (VPA), hydroxamic acids (TSA, SAHA), benzamides (Mocetinostat, 
MS-275, PD-106), and cyclic peptides (apicidin, API-D) (178). Utilization of a multitude 
of structurally divergent HDAC inhibitors in the same in vitro or in vivo models is a 
useful way to determine if the observed effect is indeed through HDAC inhibition, as it is 
unlikely that small molecules with very different structures elicit common off-target 
effects. Table 4 organizes different HDAC inhibitors by class selectivity, as well as the 
minimum effective concentrations used by our lab.   
Table 4: Standard doses, effective uses and class selectivity of HDAC inhibitors used in 
our lab. NRVM: neonatal rat ventricular myocyte; NRVF: neonatal rat ventricular 





Extending from HDACs, experts in any field of pharmacology that specialize in 
any class of small molecules, interfering/augmenting peptides, or antibodies should 
carefully consider the concentration at which the molecule is at 50% inhibitory capacity 
(IC50). This is required to determine if the specific target of pharmacological 
manipulation is actually responsible for the observed action, and for general 
reproducibility of the experiment. Our lab uses the pan-HDAC inhibitor Trichostatin A 
(TSA) at an incredibly effective concentration of 200 nM in vitro. One group 
investigating the molecular mechanisms of retinitis pigmentosa (RP) showed that 
inhibition of HDACs in retinal explants decreased activity of the poly-ADP-ribose-
polymerase and strongly reduced photoreceptor cell death, using TSA at a concentration 
of 1 μM (179). Another group found that culturing glioma cells with the global 
demethylating agent 5-aza-2’-deoxycytosine along with 100 μM TSA resulted in re-
expression of the suppressor of cellular invasion Transglutaminase 2 (TG2) (180). There 
is little question that usage of TSA in these contexts results in the observed findings the 
authors describe, but using TSA at a concentration that is 5x-500x the effective 
concentration calls into question whether inhibition of HDACs alone is responsible for 
the observed action.  
Another warranted caution while using HDAC inhibitors is to know that not all 
HDAC inhibitors elicit equal action on the cell. A seminal study published in April, 2015 
reported an enormous effort detailing acetylation signatures resulting from treatment of 
19 different HDAC inhibitors covering all 18 mammalian HDACs in human cells and 
used genetic HDAC knockout cells to confirm the findings (142). This study examined 




Isotope Labeling of Amino acids in Cell culture (SILAC). Amazingly, less changes were 
detected in acetylation sites from cells treated with the pan-HDAC inhibitor TSA (at 2 
μM) compared to the class I selective HDAC inhibitors apicidin (5 μM), Mocetinostat 
(20 μM), CI994 (50 μM), and MS-275 (5 μM). Of course, this concentration is 10x the 
concentration our lab uses for empirically effective actions of TSA. It would be 
interesting to see how many acetylation sites are detected with TSA used at 200 nM.  
Lastly, protein lysine residues are subject to a vast array of PTMs in addition to 
acetylation. Lysine is the most versatile amino acid hub for PTMs, including other acyl 
modifications (crotonylation, succinylation, malonylation), methylation, small protein 
isopeptide bonds (ubiquitination, NEDDylation, SUMOylation), and biotinylation (181-
183). With so many PTMs occupying protein lysine residues at a given time, an 
interesting postulation is what happens to proteome-wide PTMs when inhibiting global 
removal one lysine PTM? At the beginning of the work undertaken in this dissertation, 
we asked the question: when a cell is treated with an HDAC inhibitor, what happens to 
other lysine PTMs? This question inspired the findings in Chapter 2. 
 Overview of this Dissertation 
 The underlying objectives of this dissertation were to determine the molecular 
mechanisms regarding why HDAC inhibitors are efficacious in pre-clinical models of 
HF, identify new potential drug targets through examining the pharmacodynamic effects 
of HDAC inhibitors in the heart, and develop translatable evidence for the use of HDAC 
inhibitors in diseases that currently have no proven pharmacotherapeutic. Chapters 2-4 




 Chapter 2 discusses the initial paradoxical, yet physiologically consistent findings 
of HDAC inhibitors stimulating lysine SUMOylation in cardiac myocytes. If validated in 
vivo, these would potentially explain the benefits of using HDAC inhibitors, as well as 
SUMO-1 gene transfer in pre-clinical models of HF. Chapter 3 discusses a non-canonical, 
yet undiscovered role for HDAC inhibitor-mediated stimulation of JNK Interacting 
Protein-1 in cardiac myocytes. Finally, Chapter 4 describes elevated levels of HDAC 
catalytic activity and HDAC protein expression in human children with single-ventricle 
physiology, as well as translatable findings to a novel pre-clinical model of pediatric right 
ventricular hypertrophy. Chapter 5 summarizes the findings of Chapters 2-4, presents 
future directions of these studies, and provides perspectives for extending the field of 

















CLASS I HDAC INHIBITION STIMULATES CARDIAC PROTEIN 
SUMOYLATION THROUGH A POST-TRANSLATIONAL MECHANISM* 
Introduction 
Lysine residues in a variety of proteins are subject to diverse modifications, 
including acetylation, methylation, ubiquitylation and SUMOylation. The most well 
characterized post-translational modification of lysine is acetylation (181). In the context 
of chromatin, acetylation of histone tails impacts gene transcription by altering 
electrostatic interactions between DNA and nucleosomes, and by creating docking sites 
(a histone code) for multi-subunit regulatory complexes (184). Additionally, proteomic 
studies have revealed reversible acetylation of thousands of non-histone proteins that 
regulate a multitude of biological processes (139,141,164).  
Acetyl groups are conjugated to lysine by histone acetyltransferases (HATs) and 
removed from lysine by histone deacetylases (HDACs). With regard to the heart, several 
studies have shown that small molecule HDAC inhibitors have beneficial effects in pre-
clinical models of HF (146,185). HDACs are grouped into four classes and are encoded 
by 18 different genes. Class I, II, and IV HDACs require zinc as a cofactor, whereas class 
III HDACs, better known as sirtuins, require nicotinamide adenine dinucleotide as a 
cofactor for catalytic activity (136). Inhibitors of zinc-dependent HDACs have been 
shown to block pathological cardiac hypertrophy and cardiac fibrosis, and improve  
*Reprinted from Cellular Signalling, Vol. 12, Blakeslee WW, Wysoczynski CL, Fritz 
KS, Nyborg JK, Churchill ME, McKinsey TA, Class I HDAC inhibition stimulates 
cardiac protein SUMOylation through a post-translational mechanism, 2912-2920, 2014, 





cardiac contractile performance. Nonetheless, the molecular mechanisms for the 
beneficial effects of HDAC inhibitors in the setting of HF remain poorly characterized. 
Lysine SUMOylation provides another mechanism for controlling protein 
function (186,187). The four SUMO family members (SUMO-1, -2, -3 and -4) belong to 
the ubiquitin-like protein modifying family and have a characteristic β-grasp fold (188). 
SUMO-1/2/3 are covalently ligated to their targets in a manner analogous to ubiquitin 
that involves an E1 activating heterodimer (SAE1/SAE2), a single E2 conjugating 
enzyme (Ubc9), and, in many cases, an E3 SUMO ligase, which is thought to confer 
substrate specificity (186). Sentrin specific proteases (SENPs) are de-SUMOylases that 
are responsible for cleaving pro-SUMO into mature-SUMO, and also remove SUMO 
from target proteins, contributing to the dynamic nature of this lysine modification (189).  
It is well established that SUMOylation plays a role in cardiac development (190-
194). Recently, dysregulation of the SUMO pathway was also shown to contribute to the 
pathogenesis of adult HF. Myocardial expression of SUMO-1 protein was found to be 
dramatically reduced in failing human hearts and in animal models of HF (111). 
Remarkably, in rodent and pig models, recombinant adeno-associated virus (rAAV)-
mediated overexpression of SUMO-1 in the heart was demonstrated to suppress cardiac 
hypertrophy and fibrosis and improve contractile function, at least in part, through 
SUMO-1-ylation of sarcoplasmic reticulum Ca2+-ATPase SERCA2a (111,195-197). 
Given the critical roles of lysine acetylation and SUMOylation in the control of 
cardiac structure and function, we assessed the potential for crosstalk between these post-
translational modifications in the heart. Here, we define a novel role for class I HDACs 




beneficial effects of HDAC inhibitors in models of HF may in part be due to the ability of 
these compounds to stimulate SUMO-1 conjugation to proteins in cardiac myocytes and 
fibroblasts. 
Materials and Methods 
Inhibitors and Agonists 
Reagents were purchased or synthesized in-house and used at the indicated final 
concentrations. HDAC inhibitors: trichostatin A (TSA) (Sigma; 200 nM), MGCD0103 
(Selleck; 1 M), diphenylacetohydroxamic acid (DPAH) (Sigma [D6071]; 10 M), 
tubastatin A (Selleck; 1 M), and MS-275 (Selleck; 1 M). BA-60 (1 M) was 
synthesized in-house, and its purity was confirmed to be greater than 95%. Phenylephrine 
(PE), phorbol 12-myristate 13-acetate (PMA), actinomycin D (ActinoD) and 
cycloheximide (CHX) were purchased from Sigma and used at final concentrations of 10 
M, 50 nM, 1 g/mL and 100 M, respectively.  
Cell Isolation and Culture 
Neonatal rat ventricular myocytes (NRVMs) and neonatal rat ventricular fibroblasts 
(NRVFs) were prepared from hearts of 1- to 3-day old Sprague–Dawley rats, as 
previously described (198). Cells were cultured overnight on 10-cm plates coated with 
gelatin (0.2%; Sigma) in Dulbecco's Modified Eagle's Medium (DMEM) containing calf 
serum (10%), L-glutamine (2mM), and penicillin–streptomycin. After overnight culture, 
cells were washed with serum-free medium and maintained in DMEM supplemented 
with L-glutamine, penicillin–streptomycin, and Nutridoma-SP (0.1%; Roche Applied 
Science), which contains albumin, insulin, transferrin, and other defined organic and 




Langendorff-perfusion method from Sprague Dawley rats (153). NRVFs and ARVFs 
were cultured in DMEM with 20% FBS containing penicillin (100 U/mL), streptomycin 
(100 U/mL) and L-glutamine (2λ.2 g/mL) (PSG); cells were used at passage one for all 
experiments. All cell culture supplies were purchased from Cellgro (Mediatech, Inc.), 
unless otherwise noted. 
Immunoblotting and Immunoprecipitation 
Cells were washed twice in ice-cold PBS (pH 7.4) containing 20mM n-ethylmaleimide 
(NEM) (Sigma, E3876) prior to lysis. Cells were lysed in radioimmunoprecipitation 
assay buffer (RIPA) containing 50mM Tris (pH 8), 150 mM NaCl, 0.1% SDS, 0.5% 
sodium deoxycholate, 1% NP-40, 20 mM NEM, and HALT™ protease/phosphatase 
inhibitor mixture (Thermo Fisher). Cellular lysates were sonicated before clarification by 
centrifugation. Proteins were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes (BioRad) and probed with antibodies for SUMO-1 (Cell Signaling 
Technology, 4930; Santa Cruz Biotechnology, sc-5308; University of Iowa Hybridoma 
Bank, 21C7); SUMO-2/3 (Cell Signaling Technology, 4971); ubiquitin (Santa Cruz 
Biotechnology, sc-8017); cFos (Cell Signaling Technology, 4384); HDAC1 (Cell 
Signaling Technology, 5356); HDAC2 (Cell Signaling Technology, 5113); HDAC3 
(Santa Cruz Biotechnology, sc-1362λ0); αTubulin (Abcam, ab7291); RanGAP1 antibody 
#1 was kindly provided by Dr. Frauke Melchior; RanGAP1 antibody #2 (Santa Cruz 
Biotechnology, sc-25630); acetylated-lysine antibodies were used as a cocktail (Cell 
Signaling Technology, 9441 and 9681). SUMO-1 conjugates were immunoprecipitated 
using antibody-agarose conjugated beads (Santa Cruz Biotechnology, sc-5308AC). 




input sample was removed, and the remaining lysate was incubated with anti-SUMO-1 
beads at 4 °C overnight. Beads were pelleted and a supernatant sample was taken prior to 
washing beads three times with ice-cold lysis buffer and two times with ice-cold PBS. 
Immunoprecipitated SUMO-1 conjugates were resolved by SDS-PAGE and detected by 
immunoblotting. 
Lentiviral Production and Infection 
Lentiviruses were produced with pLKO.1 short hairpin RNA plasmids (Sigma) provided 
by the University of Colorado Boulder Functional Genomics Facility. On Day 1, 2 × 106 
HEK L293 cells were plated on 10-cm plates in DMEM containing calf serum (10%), L-
glutamine (2 mM), and penicillin–streptomycin. On Day 2, each plate was transfected 
with 9 g of packaging plasmid (psPAX2), 0.λ g envelope plasmid (pMD2.G), and λ g 
pLKO.1 containing shRNA sequence of interest. Plasmids were combined with a 3 L: 1 
g polyethyleneimine (PEI): DNA mixture; PEI (Polysciences, Inc., cat# 23966) was 
used at a concentration of 1 mg/mL. On Day 3, media were replaced with fresh DMEM 
containing calf serum (10%), L-glutamine (2 mM), and penicillin–streptomycin. On Day 
5, culture medium containing viral particles was passed through a 0.45 m syringe filter 
and stored at −80 °C until use. For infection of NRVMs on 60-mm plates, 3 mL of 
lentivirus-containing medium was added, and 3 L polybrene (10 mg/mL) was included 
to enhance infection efficiency. Cells were cultured for four days in serum-free DMEM 
containing Nutridoma-SP supplement and PE (10 M). Cell homogenates were prepared 
in RIPA buffer supplemented with 20 mM NEM and HALT™ protease/phosphatase 




mammalian targeting; shHDAC1, TRCN0000039402; shHDAC2, TRCN0000039395; 
shHDAC3, TRCN0000318152. 
SENP Activity Assay 
Sentrin specific protease (SENP) activity was assessed as described previously (199). 
Cardiac fibroblasts were treated with vehicle (DMSO) or MGCD0103 for 48 h. Some 
cells received vehicle and were heat shocked at 43 °C for 30 min prior to lysis. Cells were 
lysed in PBS pH 7.4 supplemented with 300 mM NaCl and 0.5% Triton X-100. Protein 
homogenates were incubated with 500 nM SUMO-1-7-amidomethylcoumarin (AMC) 
(Enzo Life Sciences) in 110 L of assay buffer (50 mM Tris HCl, pH 7.5, 0.1 mg/mL 
bovine serum albumin, and 10 mM DTT). Hydrolysis of SUMO-1 AMC was measured 
by determining the increase in fluorescence ( ex = 340 nm and em = 440 nm) every 30 s 
for 2 h using a BioTek Synergy 2 plate reader. 
Purification of Recombinant Proteins 
Recombinant protein components of the SUMO conjugation machinery were produced in 
BL21(DE3) Escherichia coli using pET28a-Aos1 (SAE1), pET28b-Uba2 (SAE2), 
pET23a-Ubc9, pET-11a- SUMO-1, and pET11-hRanGAP1, and were purified as 
previously described (200). 
Chemical Acetylation Followed by In Vitro SUMOylation 
Chemical acetylation was adapted from a previously described method (201). 
Recombinant forms of each component of the SUMO conjugation machinery (1 g each) 
were chemically acetylated by 0.1 mM acetic anhydride (Sigma, 320102) in PBS for 1 h 
at room temperature. After chemical acetylation, proteins were resolved by SDS-PAGE 




confirmed by Coomassie Brilliant Blue staining. Pre-acetylated proteins were 
incorporated into in vitro SUMOylation assays with RanGAP1 substrate based on prior 
optimization studies; SAE1/SAE2 (140 ng), Ubc9 (220 ng), SUMO-1 (2 g), and 
RanGAP1 (2 g, unacetylated) (202). Reaction buffer consisted of 40 mM HEPES pH 
7.3, 220 mM KOAc, 4mM Mg(OAc)2, 4mM DTT, and protease/phosphatase inhibitor 
cocktail (Thermo Fisher). Reactions were carried out at 30 °C for 30 min in the absence 
or presence of ATP (5 mM) and terminated by boiling in SDS-PAGE sample buffer. 
In Vitro Acetylation by p300 Followed by In Vitro SUMOylation 
Recombinant p300 histone acetyltransferase was produced as previously described (203). 
Reactions were performed with recombinant SUMO-1, SAE1/2 and Ubcλ (1 g each) in 
reaction buffer containing 25 mM Tris HCl pH 7.9, 50 mM KCl, 6.25 mM MgCl2, 10% 
glycerol, 1 mM DTT and p300 for 1 h at 30 °C. Assessment of protein acetylation and i  
vitro SUMOylation activity of pre-acetylated proteins was performed as described above 
for acetic anhydride. 
Results 
Selective Inhibition of HDAC1 and HDAC2 Stimulates Protein SUMOylation in 
Cardiac Myocytes and Fibroblasts 
 Since acetylation or SUMOylation of a given lysine residue occurs in a mutually 
exclusive manner (181), we hypothesized that globally increasing protein acetylation 
through the use of an HDAC inhibitor would result in the suppression of SUMO-1 
conjugation. To address this hypothesis, primary neonatal rat ventricular myocytes 
(NRVMs) were treated with the HDAC inhibitor trichostatin A (TSA) over a time course 




rather than inhibiting SUMOylation, TSA treatment resulted in a robust, time-dependent 
accumulation of high molecular weight SUMO-1 conjugated proteins. A similar increase 
in protein SUMOylation was observed in primary rat cardiac fibroblasts treated with 
TSA, although the stimulatory effect in these cells appeared to be transient compared to 
cardiac myocytes (Fig. 1B). 
 
Fig. 1. HDAC inhibition stimulates SUMOylation in cardiac cells. (A) Neonatal rat 
ventricular myocytes (NRVMs) were treated with the pan-HDAC inhibitor trichostatin A 
(TSA) for the indicated amounts of time. SUMO-1 conjugates were examined by 
immunoblotting. (B) Primary adult rat cardiac fibroblasts were serum starved for 24 h 
prior to treatment with TSA. Arrows indicate the high molecular weight SUMO 
conjugates that are referenced throughout the text. 
 
TSA is a pan-HDAC inhibitor that efficiently inhibits the catalytic activity of at 
least nine Zn2+-dependent HDACs (HDACs 1–9) (204). The recent discovery of isoform-
selective HDAC inhibitors provides an opportunity to use a chemical biological approach 
to more precisely address the role of specific HDACs in the control of a given process. 
For example, MGCD0103 and MS-275 are benzamide-containing compounds that are 




benzamide derivatives such as biaryl-60 (BA-60) selectively inhibit HDACs-1 and -2 
(205,206). Diphenylacetohydroxamic acid (DPAH) blocks the activity of class IIa 
HDACs (HDACs-4, -5, -7 and -9) (207), while tubastatin A is highly specific for 
HDAC6, which is a class IIb HDAC (175). Selectivity profiles of these compounds are 
summarized in Fig. 2A. 
 As shown in Fig. 2B, MGCD0103 and MS-275 induced SUMOylation in NRVMs 
as efficiently as TSA, suggesting that a class I HDAC(s) regulates this post-translational 
modification. Class I HDAC inhibition was equally effective at promoting SUMOylation 
in hypertrophic cardiomyocytes and unstimulated cardiomyocytes (Fig. 2B and C). Class 
IIa and IIb inhibition failed to stimulate SUMO-1 conjugation. Remarkably, selective 
inhibition of only HDAC1 and HDAC2 with BA60 was sufficient to promote SUMO-1 
conjugation in both cardiomyocytes and cardiac fibroblasts (Fig. 2C and D). These 
findings define a novel role for HDAC1 and/or HDAC2 as negative regulators of protein 
SUMOylation in the two dominant cell types in the heart, myocytes and fibroblasts. 
 HDAC inhibitor-mediated SUMOylation appeared to occur primarily on high 
molecular weight proteins. To more accurately characterize SUMO-1 targets that were 
enhanced by class I HDAC inhibition, cardiac fibroblast lysates were resolved through a 
lower percentage polyacrylamide gel and subjected to anti-SUMO-1 immunoblotting. 
Two prominent basally SUMOylated proteins were detected near the 100 kDa marker and 
MGCD0103 treatment enhanced SUMO-1 conjugation to both of these targets (Fig. 2E). 
Based on molecular weight, it is predicted that the more rapidly migrating protein is 
RanGAP1, which is the most stably SUMOylated protein described to date (208). 





Figure 2. Selective inhibition of HDAC1 and HDAC2 is sufficient to stimulated 







Fig. 2. Selective inhibition of HDAC1 and HDAC2 is sufficient to stimulated 
SUMOylation in cardiac myocytes and cardiac fibroblasts. (A) Selectivity profiles for the 
indicated HDAC inhibitors are shown; X = inhibited. (B) NRVMs were stimulated with 
phenylephrine (PE) in the absence or presence of the indicated HDAC inhibitors for 48 h; 
DMSO vehicle (Veh.; 0.1% final concentration) was used as a negative control. SUMO-1 
conjugates were examined by immunoblotting. (C) Unstimulated NRVMs were treated 
for 48 h with the indicated HDAC inhibitors prior to immunoblotting for SUMO-1 
conjugates. (D) Neonatal rat ventricular fibroblasts were serum-starved for 24 h prior to 
treatment with the indicated HDAC inhibitors for 48 h. (E) Independent plates of adult rat 
ventricular fibroblasts were serum-starved for 24 h prior to treatment with MGCD. 
SUMO-1 conjugates were resolved on a 7.5% polyacrylamide gel as opposed to (A-D), 



















proteins ranging from 100 kDa to over 170 kDa, suggesting a general role of HDAC1/2 
in the control of SUMO-1 conjugation and/or cleavage. 
HDAC2 Suppresses Cardiac Protein SUMO-1-ylation 
 To directly assess whether class I HDAC inhibition stimulates RanGAP1 
SUMOylation, NRVMs were treated with MGCD0103 or BA60 for 48 h and levels of 
free RanGAP1 and SUMO-1-conjugated RanGAP1 were assessed by immunoblotting. 
Two distinct antibodies revealed elevated levels of SUMO-1-ylated RanGAP1 in 
NRVMs treated with the HDAC inhibitors (upper bands). 
 Since BA60 selectively inhibits HDAC1 and HDAC2, experiments were next 
performed to determine the relative contribution of these HDAC isoforms to the control 
of cardiac protein SUMOylation. Lentiviral expression of short hairpin RNAs (shRNAs) 
effectively and selectively inhibited the expression of endogenous HDAC1, HDAC2 or 
HDAC3 protein in NRVMs (Fig. 3B, top panel). Remarkably, knockdown of HDAC2 
alone dramatically increased the abundance of multiple SUMO-1-conjugated proteins in 
NRVMs, while knockdown of HDAC1 or HDAC3 failed to stimulate SUMOylation (Fig. 
3B, middle panel). Subsequent immunoblotting revealed a modest increase in RanGAP1 
SUMOylation in cells in which HDAC2 expression was suppressed (Fig. 3B, bottom 






Fig. 3. HDAC2 regulates cardiac protein SUMOylation. (A) NRVMs were treated with 
MGCD0103 or BA60 for 48 h, and protein homogenates were immunoblotted with two 
distinct antibodies that detect free RanGAP1 (lower band) and SUMO-1-ylated 
RanGAP1 (upper band). (B) NRVMs were infected with lentiviruses encoding shRNAs 
directed toward HDAC1, HDAC2 or HDAC3. shControl is an shRNA that is predicted to 
fail to target any mammalian mRNA transcript. After 96 h of infection in the presence of 
PE, cells were lysed and HDAC1, HDAC2, HDAC3, SUMO-1, and RanGAP1 were 






Class I HDAC Inhibition Enriches for SUMO-1 Conjugates Rather Than SUMO-2/3 
Conjugates in Cardiac Myocytes and Fibroblasts 
 SUMO-1 and its paralogs, SUMO-2/3, are conjugated to target proteins via the 
same core enzymatic machinery (186,209). However, while SUMO-1 is conjugated to 
lysine as a monomer, SUMO-2/3 can form chains analogous to ubiquitin (210). Proteins 
that are modified by SUMO-2/3 appear as a stepwise ladder when resolved through 
polyacrylamide gels. Given the periodicity of the SUMO-1-conjugated proteins derived 
from HDAC inhibitor treated cells (Fig. 2E), sequential immunoprecipitation (IP) and 
immunoblotting was performed to determine if the target proteins were also conjugated to 
SUMO-2/3 and/or ubiquitin. High molecular weight SUMO-1 conjugated proteins were 
quantitatively immunoprecipitated with a SUMO-1-specific antibody (Fig. 4A). 
Remarkably, neither SUMO-2/3 nor ubiquitin conjugates were detected in SUMO-1 
immunoprecipitates from DMSO or HDAC inhibitor-treated cells (Fig. 4B and C). 
Consistent with these findings, analysis of whole cell lysates revealed that, relative to 
SUMO-1, pan- and class I HDAC inhibition only modestly elevated SUMO-2/3 
conjugates in cardiomyocytes and cardiac fibroblasts (Fig. 4D). These findings suggest 





Fig. 4. Inhibition of class I HDACs preferentially enhances SUMO-1 conjugation. 
SUMO-1 conjugates from DMSO vehicle or HDAC inhibitor-treated cardiac fibroblasts 
(A) or NRVMs (B and C) were immunoprecipitated (IP) with anti-SUMO-1 antibody-
conjugated beads and immunoblotted (IB) with either anti-SUMO-1 antibody (A), anti-
SUMO-2/3 antibody (B), or anti-ubiquitin antibody (C). Input = 10% of pre-IP volume; 
IP supernatant (Sup) = 10% of post-IP volume; pellet = immunoprecipitate. 
Immunoglobulin heavy (IgH) and light (IgL) chains from the IP antibody are indicated. 
(D) NRVMs or 24 h serum-starved adult rat ventricular fibroblasts were treated with 
DMSO, TSA or MGCD for 48 h, and SUMO-2/3 conjugates were detected by 
immunoblotting. 
 
HDAC Inhibitor-Mediated SUMOylation Occurs Independently of De Novo Protein 
Synthesis 
HDAC inhibitors have profound effects on gene expression. To begin to address 
the mechanism by which HDAC inhibition leads to accumulation of SUMOylated 
proteins, we determined whether de novo gene expression is required for the HDAC 




presence of actinomycin D (ActD), which blocks gene transcription. In order to minimize 
the duration that cells were exposed to ActD, which is cytotoxic, these studies were 
performed with TSA; TSA rapidly inhibits HDAC catalytic activity while benzamide 
class I HDAC inhibitors such as MGCD0103 have a slow on-rate (211,212). ActD 
treatment alone led to modest SUMOylation in NRVMs (Fig. 5A, lane 3). Importantly, 
TSA efficiently promoted SUMOylation in NRVMs co-treated with ActD (Fig. 5A, 
compare lanes 2 and 4). The integrity of the ActD preparation was confirmed by its 
ability to block PE-mediated induction of the immediate early gene, cFos (lower panel). 
HDAC inhibition also induced cFos protein expression, which was blocked by ActD 
treatment. 
To rule out the possibility that induction of SUMO-1 conjugates by ActD alone 
complicated interpretation of the data, experiments were also performed with 
cycloheximide (CHX) to block de novo protein synthesis. Consistent with the findings 
made with ActD, TSA was still capable of enhancing protein SUMOylation in NRVMs 
and cardiac fibroblasts treated with CHX (Fig. 5B and C). However, unlike what was 
observed with ActD, CHX treatment did result in a modest reduction in the degree of 
induction of SUMO-1 conjugates by TSA (Fig. 5B and C, lanes 2 and 4). The data 
suggest that HDAC inhibition leads to accumulation of SUMO- 1-conjugated proteins 
through a post-translational mechanism. Based on the findings with CHX, we propose 
that HDAC inhibition enhances SUMOylation of a pre-existing pool of protein that is 





Fig. 5. Class I HDAC inhibitor-mediated SUMOylation does not require d novo gene 














Fig. 5. Class I HDAC inhibitor-mediated SUMOylation does not require de novo gene 
transcription or protein synthesis. (A) NRVMs were pre-treated with actinomycin D 
(ActD) for 2 h to block gene transcription, and were subsequently exposed to either 
vehicle (DMSO; -) or TSA for 4 h. As controls, some cells received PE for 2 h in the 
absence or presence of ActD. Protein homogenates were immunoblotted with anti-
SUMO-1 antibody. In parallel, cFos protein was assessed to confirm that ActD efficiently 
inhibited gene expression. (B) NRVMs were pre-treated with the protein translation 
inhibitor cycloheximide (CHX) for 30 min, and were subsequently exposed to vehicle 
(DMSO; -) or TSA for 4 h. Immunoblotting was performed with anti-SUMO-1 antibody 
or cFos antibody to confirm CHX efficacy. (C) Adult rat ventricular fibroblasts were 
serum-starved for 24 h, pre-treated with CHX for 30 min, and exposed to DMSO or TSA 
for 4 h. As controls, some cells received PMA for 2 h in the absence or presence of of 
CHX. ActD did not block TSA-mediated SUMO-1-ylation (A), and only partially 
reduced SUMO-1 conjugation in cardiac myocytes (B) and fibroblasts (C), suggesting 




















Class I HDAC Inhibition does not Suppress SENP Catalytic Activity 
The increase in protein SUMOylation in HDAC inhibitor-treated cells could be 
due to stimulation of SUMO conjugation or suppression of de-SUMOylation. To address 
the latter possibility, we assessed the impact of class I HDAC inhibition on the catalytic 
activity of sentrin-specific proteases (SENPs), which are a family of enzymes that cleave 
SUMO conjugates from proteins. Cardiac fibroblasts were treated with MGCD0103 or 
vehicle control. As a positive control, a third group of cells was subjected to heat shock, 
which has previously been shown to inhibit SENP activity (199). After cell lysis, SENP 
activity was quantified by incubation of protein homogenates with a SUMO-1-7-
amidomethylcoumarin (AMC) substrate; de-SUMOylation of the substrate results in 
enhanced fluorescence. As shown in Fig. 6, SENP activity was similar in extracts from 
MGCD0103-treated NRVMs and untreated controls, while heat shock led to a profound 
decrease in SENP catalytic activity. These data suggest that the post-translational 
mechanism by which HDAC inhibition enhances SUMOylation does not involve 





Fig. 6. Global SENP catalytic activity is not suppressed by a class I HDAC inhibitor. 
Adult rat ventricular fibroblasts were serum-starved for 24 h and treated with DMSO 
vehicle or the class I HDAC inhibitor MGCD for 48 h. As controls, some cells were 
subjected to 43 °C for 30 min prior lysis. Protein homogenates were incubated with a 
SUMO-1-AMC probe and de-SUMOylase activity (as measured by increased 
fluorescence) was monitored over 2 h. Heat shock inactivates SENPs and served as a 
positive control. For each condition, homogenates from three independent plates of cell
were pooled for the assessment of SENP activity. 
 
 
Multiple Components of the SUMO Conjugation Machinery are Acetylated on Lysine 
Residues In Vitro 
Additional experiments were performed to address the possibility that acetylation 
regulates proteins that control SUMO conjugation. Components of the in vitro 
SUMOylation assay that was employed for these studies are shown in Fig. 7A. 
Recombinant forms of the E1 activating enzyme complex (SAE1/SAE2), the E2 




were produced in E. coli. Immunoblotting with an anti-acetyl-lysine antibody revealed 
that SAE1, SAE2, Ubc9 and SUMO-1 were all capable of being chemically acetylated 
with acetic anhydride in vitro, albeit to different extents (Fig. 7B). Additionally, SAE2 
and Ubc9 were efficiently acetylated by recombinant p300, which possesses intrinsic 
histone acetyltransferase (HAT) activity (Fig. 7C). However, p300 was unable to 
acetylate SAE1 and SUMO-1 in vitro (Fig. 7C, lanes 4 and 8). 
To assess whether acetylation affects SUMO conjugation, SAE1/2, Ubc9 and 
SUMO-1 were pre-acetylated with acetic anhydride or p300 and incorporated into in vitr  
enzymatic assays with ATP and recombinant RanGAP1 substrate. Neither mode of pre-
acetylation resulted in enhanced conjugation of SUMO-1 to RanGAP1 (Fig. 7D and E). 
Thus, under these experimental conditions, acetylation of core SUMO conjugation 





Fig. 7. Acetylation of SUMO conjugation machinery. (A) Schematic depiction of the in 
vitro SUMOylation assay. (B) The indicated recombinant proteins were incubated for 1 h 
with acetic anhydride to assess non-enzymatic acetylation of the proteins. Proteins were 
resolved by SDS-PAGE and either immunoblotted with anti-acetyl-lysine antibody (top 
panel) or stained with Coomassie Blue dye (bottom panel); *SAE1, **SAE2, 
***presumed degradation product of SAE2. (C) Recombinant proteins were incubated 
for 1 h with p300 to assess their capacity to be enzymatically acetylated. Samples were 
analyzed as in (B); **SAE2. Note that p300 (the upper-most acetylated protein) 
undergoes auto-acetylation (arrow). (D) In vitro SUMOylation assays were performed as 
outlined in (A) after acetic anhydride treatment (D) or exposure to p300 (E). Reactions 
were terminated at the indicated times. Proteins were resolved by SDS-PAGE and stained 







The findings of this study establish a novel role for class I HDACs, specifically 
HDAC2, in the control of protein SUMOylation in cardiac myocytes and fibroblasts. 
Since combined inhibition of HDAC1/2 catalytic activity (Fig. 2), or selective 
knockdown of HDAC2 expression (Fig. 3), leads to the accumulation of SUMO-1-
conjugated proteins in cardiac cells, the results suggest that HDAC2 functions as an 
endogenous inhibitor of SUMOylation in the heart. The work extends the ever-expanding 
list of non-canonical functions of HDACs, and reversible lysine acetylation, beyond the 
control of epigenetics and gene transcription. 
Crosstalk between acetylation and SUMOylation at the level of individual 
substrates has previously been demonstrated. For example, acetylation of a conserved 
lysine residue in the myocyte enhancer factor 2 (MEF2) transcription factor stimulates 
MEF2-dependent transcription of downstream target genes (213). Conversely, when this 
same lysine residue is SUMOylated, MEF2 transcriptional activity is repressed. Similar 
to MEF2, acetylation or SUMOylation of lysine-386 in the p53 transcription factor has 
opposing effects on p53 target gene activation (214). 
More recently, acetylation has emerged as a mechanism for influencing the 
activity of components of the SUMO conjugation machinery. Consistent with our 
findings (Fig. 7), the E2 conjugating enzyme Ubc9 was shown to be acetylated at lysine-
65, resulting in differential SUMOylation of downstream substrates (215). In addition, 
two studies demonstrated that SUMO itself is acetylated. When conjugated to p53, 
SUMO-1 is either unacetylated or acetylated on lysine-37, and the acetylation state of 




SUMO-1 or SUMO-2/3 was also shown to negatively regulate interactions between 
SUMO and proteins harboring SUMO-interaction motifs (SIMs) (217). It is noteworthy 
that we failed to detect significant levels of SUMO-1 acetylation in our in vitro assays 
(Fig. 7). This discrepancy could be due to the antibodies that were used for 
immunoblotting. We employed pan anti-acetyl-lysine antibodies, while the 
aforementioned studies used an antibody specific for acetylated lysine-37 of SUMO-1; it 
is possible that the pan-anti-acetyl-antibodies fail to recognize acetyl-SUMO-1. 
Enhancement of global SUMOylation has been observed in cells exposed to 
osmotic and oxidative stress, heat shock, ethanol and the lipid peroxidation product 4-
hydroxy-nonenal (4-HNE) (218-220). There is also a rich body of literature showing that 
ischemia enhances the formation of SUMO-1/2/3 conjugates in organs such as the brain 
and kidney (221). Much of this elegant work was performed using a ground squirrel 
model of hibernation torpor, where oxygen and glucose deprivation during torpor was 
demonstrated to result in a dramatic increase in SUMO-1 and SUMO-2/3 conjugation to 
proteins in a variety of organs (222). SUMOylation appears to provide a mechanism for 
ischemic tolerance (223). Interestingly, HDAC inhibitors have been shown to be 
protective in pre-clinical models of ischemic brain injury and in models of ischemic 
cardiomyopathy (224-227). Based on our findings, it is possible that at least a portion of 
the observed protective effects of HDAC inhibitors in the setting of ischemia are due to 
stimulation of SUMOylation. 
The molecular basis for the enhancement of cardiac protein SUMOylation by 
HDAC inhibitors remains unknown. Given that de novo protein synthesis is not required 




was due to stimulation of SUMO conjugation or suppression of de-SUMOylation. 
Concerning the latter possibility, class I HDAC inhibition did not reduce global SENP 
activity in cardiac fibroblasts (Fig. 6). Although it remains possible that HDACs have as-
yet-unidentified effects on de-SUMOylation via one or more of the seven SENP family 
members, these data suggest that HDAC inhibition targets components of the SUMO 
conjugation machinery to promote SUMOylation of proteins. Surprisingly, acetylation of 
the E1 activating enzyme complex (SAE1/2) or Ubc9 failed to enhance SUMO-1 
conjugation to RanGAP1 in our in vitro assay (Fig. 7). While it is possible that E1 or E2 
acetylation stimulates SUMOylation of substrates other than RanGAP1, we favor a model 
in which acetylation of an E3 SUMO ligase(s) promotes SUMO-1 conjugation to select 
targets. Although SUMOylation can proceed in the absence of an E3 ligase, these 
enzymes enhance conjugation and confer target specificity to the reaction (186). There 
are seven bona fide E3 ligases in mammals and, intriguingly, interrogation of databases 
associated with proteomic studies reveals that several of these enzymes are acetylated on 
lysine residues (139,141) (Table 5). Elucidation of the identity of proteins within the pool 
of high molecular weight factors that are SUMOylated in an HDAC inhibitor-dependent 
manner should facilitate efforts to define the possible role of reversible lysine acetylation 
in the control of E3 SUMO ligases. 
Conclusions 
Inhibition of class I HDAC catalytic activity stimulates SUMO-1-ylation in the 
two most abundant cell types in the heart, cardiomyocytes and cardiac fibroblasts. HDAC 
inhibition elicits cardiac protein SUMOylation through a post-translational mechanism 




machinery. Independently, HDAC inhibition and SUMO-1 overexpression suppress 
pathological cardiac remodeling in response to stresses such as pressure overload and 
myocardial infarction in pre-clinical models. Thus, our findings raise the intriguing 
possibility that concomitant HDAC inhibitor therapy and SUMO-1 gene transfer will 
provide synergistic efficacy in the setting of HF. 
Limitations and Future Directions 
There are a few limitations to these studies. As alluded to above, acetyl-lysine 
antibodies are typically raised against acetylated-lysine peptides with the amino acid 
flanking sequences of histones. A consensus amino acid sequence for lysine acetylation 
does not exist, making the flanking residues of acetyl-lysine very diverse. Therefore, the 
antibodies we use may not recognize the flanking regions of certain acetylated SCM 
lysine residues, for example, on SUMO-1. Also, by chemically acetylating theoretically 
every exposed lysine residue in our in vitro SUMOylation assay, we may actually be 
inhibiting SCM catalytic activity as seen in Figure 7D.  
Another explanation for our enzymatic n vitro acetylation assay failing to 
stimulate SUMOylation is that the SCM may be acetylated by a HAT other than p300. 
Other HATs such as: the Gcn5-related N-acetyltransferases (i.e. Gcn5 and PCAF), the 
MYST family of HATs, or other nuclear receptor co-activated HATs (i.e. Rtt109 and 
CLOCK), could be tested in our enzymatic in vitro acetylation assay. 
Recently, we have been able to experimentally knockdown SUMO-1 in cultured 
cells using adenovirus encoding shRNA directed toward SUMO-1, as depicted in Figure 
8. The very bottom bands of these two immunoblots at the 15/10 kDa range are the 




This should prove to be a valuable reagent in subsequent studies. Overexpression 
of SUMO-1 was shown to be anti-hypertrophic in NRVMs (197). An interesting follow-
up study would be to test whether SUMOylation is necessary for HDACi-mediated 
blockade of cardiac hypertrophy in vitro. As will be mentioned in the next chapter, our 
lab recently gained the ability to perform RNA sequencing experiments. It will be very 
interesting to determine what transcriptome-wide changes occur in the presence or 
absence of SUMO-1 in cardiac cells treated with HDAC inhibitors. 
 
Fig. 8. Short-hairpin RNA (shRNA)-mediated knockdown of SUMO-1 in H9C2 rat 
myoblast cells. First two lanes were infected with non-mammalian targeting shRNA 
(shControl) and increasing amounts of shSUMO-1. (A) Immunoblot was probed with 
anti-SUMO-1 from the University of Iowa Hybridoma Bank. (B) Immunoblot was 
probed with anti-SUMO-1 from Cell Signaling Technology. 
 
Another fascinating finding from this study (197), which will appear 
serendipitous from the results of the following chapter, is the ability of SUMO-1 




validated in Figure 9, but need to be repeated. It will be interesting to determine if 
HDAC-inhibitor mediated suppression of JNK activation requires SUMO-1-ylation. 
 
Fig. 9. Overexpression of epitope-tagged SUMO-1 blocks JNK activation in NRVMs. 
NRVMs were infected at the moment of plating with adenovirus encoding either beta-
galactosidase (gal) or HA-SUMO-1. 24 h after infection, NRVMs were treated or co-
treated with DMSO (Veh.), phenylephrine (PE), and trichostatin A (TSA) as indicated 
above for 24 h. 
 
These observations also need to be confirmed in vivo. Molecular detection of 
SUMOylation and the peak of maximal efficacy of HDAC inhibitor pharamcodynamics 
can be tricky to find the best time point when harvesting tissues. A proper experiment 
would be to administer a pan-HDAC inhibitor (ITF2357) by intraperitoneal injection into 




each mouse by 1 hour, flush the hearts with saline containing 20mM NEM and flash 
freeze each heart. This would be an accurate time point experiment assessing maximal 
HDAC-inhibitor mediated SUMOylation in the mouse heart compared to vehicle injected 
controls.  
 The mechanism for HDAC inhibitor/mediated SUMOylation still remains to be 
elucidated. Several components of SUMO conjugation pathway have been found to be 
acetylated, many on multiple sites (Table 5). It will be interesting to see if one of these 
acetylation marks is responsible for increased SUMO conjugation activity. 
Table 5: Acetylation targets and specific acetyl-lysine residues in the SUMO conjugation 
pathway (140, 142).  
 
Additionally, as SUMO-1-ylation and acetylation modify hundreds to thousands 
of protein respectively, experiments designed to test whether concomitant HDAC 
inhibitor therapy and SUMO-1 gene transfer provide synergistic efficacy in HF models 






HDAC REGULATION OF JNK INTERACTING PROTEIN-1 (JIP-1) IN 
CARDIOMYOCYTES 
Introduction 
 One of the most extensively studied molecular pathways involved in signal 
transduction is the c-Jun N-terminal Kinase (JNK) mitogen activated protein kinase 
(MAPK) pathway. Extracellular stimuli or cell stress activate JNK signaling by a 
phosphorylation cascade, in which every member of the signaling pathway is activated by 
dual phosphorylation on a Threonine-X(any amino acid)-Tyrosine (TxY) motif. The 
signal is initiated by MAPKKKs (MAP3Ks; ASK1(228), MEKK(229,230), MLK(231), 
TAK1(232), and TPL-2(233); all of which have multiple members), which then 
phosphorylate MAPKKs (MAP2Ks; MKK4(234) and MKK7(235)), which then 
phosphorylate JNK MAPKs (JNK1(236), JNK2(237), and JNK3(238)). Phosphorylated 
(activated) JNK subsequently phosphorylates and activates transcription factors (i.e. 
ATF-2(239), ELK-1(240), c-Jun(241)), which in turn facilitate transcription of gene 
programs in response the extracellular stimuli or cell stress (242). As mentioned above, 
JNK is encoded by three distinct genes, with ubiquitous expression of JNK1 and JNK2 
and tissue-enriched expression of JNK3 in the brain, heart and testis (237). Expression of 
JNK1-3 gives rise to a total of ten alternatively spliced JNK isoforms as well as products 
with and without a C-terminal extension migrating at 55 kDa or 46 kDa in denaturing 
polyacrylamide gels (237). 
 The role of JNK in cardiac remodeling has been the topic of much controversy. 




others have failed to see JNK activation in failing human hearts (245,246). It should be 
noted that activation of JNK was measured in several different ways between these 
studies, including: in-gel JNK kinase assay (243), immunoblot measuring phospho-JNK 
(244),  and phosphorylation signal of GST-tagged c-Jun in an vitro kinase assay using 
tissue homogenates from failing human hearts (245,246). JNK signaling was initially 
thought to play a critical role in cardiac hypertrophy, due to JNK1/2 being acutely 
activated after stimulation in cultured cardiac myocytes (247-249), mice subjected to 
TAC (250), adult rats subjected to supravalvular pressure overload (251), and a rabbit 
model of ischemia/reperfusion (252). Genetic loss-of-function studies employing three 
allele combinatorial deletions of JNK1/2 and dominant-negative (dn) forms of JNK1, 
JNK2 showed an enhanced hypertrophic growth in mice subjected to aortic banding, 
indicating that JNK signaling is present to blunt cardiac growth in response to stress 
(253). Another important observation from this study was the ability of an MKK7-JNK1 
fusion protein to blunt hypertrophic growth induced by the activated CaN transgene in 
the heart, implicating the possibility that JNK blunts hypertrophic growth through 
antagonizing NFAT-CaN signaling.  
The role in progression of cardiac hypertrophy for JNK’s direct upstream 
activator MKK7 has conflicting results in vitro vs. in vivo. In vitro, adenoviral-mediated 
overexpression of MKK7 served as a potent stimulator of cardiomyocyte hypertrophy as 
well as JNK activation (254,255). Consequently, expression of a cardiac-specific 
constitutively activated MKK7, resulting in robust JNK activation; decreased expression 
of connexin43, leading to loss of gap junctions in the myocardium; and pathological 




Overexpression of a dominant negative form of JNK’s other direct upstream activator 
MKK4, where a critical lysine residue in the ATP binding site of MKK4 was mutated to 
arginine, inhibited ET-1-induced increase in protein synthesis in cultured cardiac 
myocytes (258) and inhibited pressure-overload induced cardiac hypertrophy (251).
However, the cardioprotective effects of dnMKK4 may be independent of JNK due to 
MKK4’s ability to phosphorylate kinases other than JNK1-3 in other cell types (259), as 
well as dnJNK1, dnJNK2 and the JNK-specific phosphatase (M3/6) failing to block 
agonist-induced hypertrophy in cultured cardiac myocytes (253). Though MKK4 appears 
to be an important regulator of the cardiac hypertrophic response in vivo, doubts remain 
that the JNKs themselves are necessary modulators of cardiac hypertrophy in vivo (260).   
 Central to MAPK signaling are the ability of scaffold proteins to bind and 
organize select members of the MAP3K => MAP2K => MAPK signaling pathways for 
precise control of JNK activity in vivo following initiation from cell exposure to 
cytokines, growth factors and changes to the physicochemical properties of the cellular 
environment (242). The MAP3K, MEKK1 has the ability to serve as a sequential MAPK 
activation scaffold with MKK4 and JNK (261). -Arrestin-2 is recruited to seven-
transmembrane GPCRs to downregulate heterotrimeric G-protein signaling and has been 
suggested to play a role in the GPCR-mediated activation of JNK3 through organization 
of ASK1-MKK4-JNK3 (262). The focal adhesion adapter molecule CrKII was found to 
coimmunoprecipitate with the MAP4K HPK1, MKK4 and JNK in cells exposed to Rac1 
and epidermal growth factor (263). Also, the large actin-binding protein filamin was 
shown to interact with MKK4 and be necessary for Tumor Necrosis Factor- (TNF ) 




of scaffold molecules to coordinate JNK activation through different stimuli and 
upstream activators.   
 A few years ago, our lab demonstrated the ability of class I specific HDAC 
inhibitors to block agonist-induced ERK and JNK phosphorylation. Treatment with the 
transcription inhibitor ActD as well as the protein-tyrosine phosphatase inhibitor 
pervanadate rescued HDAC inhibitor-mediated suppression of pERK, but not pJNK 
(265). These findings led us down two hypothetical pathways. The first was testing the 
hypothesis of whether direct acetylation of JNK itself or its directly upstream MAP2K, 
MKK7, was inhibiting JNK activation. Adenoviral-mediated overexpression of an 
MKK7-JNK1 gain-of-function construct was employed in cultured cardiac myocytes and 
treated with a pan- and class I selective HDAC inhibitor, TSA and Mocetinostat 
respectively. We hypothesized that due to the near complete blockade of JNK activation 
by HDACi, we would see attenuation of phosphorylation of JNK on the gain-of-function 
fusion construct. The typical robust blockade of pJNK with both of these compounds 
showed no change on this gain-of-function construct, leading us to test another 
hypothesis. Results from a MAPK PCR array comparing expression of MAPK pathway 
components in cultured cardiac myocytes, with and without an HDAC inhibitor showed 
significantly elevated transcript levels of the scaffold protein JNK-Interacting Protein-1 
(JIP-1). JIP-1 functions as a cargo molecule with a C-terminal kinesin light chain binding 
motif (266), as well as a JNK scaffold that coordinates the MAP4K HIPK1, MAP3K 
MLK, MKK7 and JNK among other binding partners (267). 
The role of JIP-1 is currently a topic of intense research in neurons, with JIP-1 




Interestingly, a phosphomimetic S421D JIP-1 drives anterograde transport of 
autophagosomes, while a phosphodeficient mutant S421A rescues retrograde transport 
down the axon of neurons. It should be noted that two prominent bands of JIP-1 are 
present at baseline in these neurons at ~100 kDa and ~115 kDa, with the larger isoform 
coimmunoprecipitating with LC3 containing autophagosomes. Another recently 
described neuronal role for JIP-1 occurs in Alzheimer’s disease pathogenesis. The 
Amyloid Precursor Intracellular Domain (AICD), which is simultaneously generated with 
the Alzheimer’s disease hallmark amyloid beta peptides, was overexpressed in JIP-1 
knockout mice and demonstrated protection from synaptic loss and improved 
performance in behavioral tests compared to mice with normal levels of JIP-1 (269). JIP-
1 is also known as Islet Brain-1 for its role in the transactivation of the GLUT2 gene in 
insulin secreting pancreatic beta-cells (270). 
 The role of JIP-1 in the heart remains poorly characterized. Overexpression of the 
JNK binding domain of JIP-1 in cardiomyocytes, which has been shown to bind to JNK 
and inhibit downstream JNK signaling when overexpressed, inhibited activation of ET-1 
and PE inducible JNK target genes (271). This was assessed by blunting of the Fetal 
Gene Program (FGP) markers that occur during cardiac remodeling, in which ectopic 
JIP-1 attenuated the expected ET-1 and PE-induced increase in ANF, -myosin heavy 
chain ( -MHC), and skeletal muscle –actin (Sk A). Also, ectopic JIP-1 also slightly 
reduced myocyte size in response to PE but not ET-1. It should be noted that neither the 
phosphorylation level of JNK, nor the activity of JNK on a recombinant JNK target 
protein were assessed. Another study investigated the role of the JNK/JIP-1 axis in the 




phosphorylation of GST-c-Jun incubated with cytosolic rat cardiac homogenates, and was 
elevated in simulated MI samples. Adenoviral-mediated delivery of JIP-1 into H9C2s 
subjected to simulated MI attenuated GST-c-Jun phosphorylation, as well as increased 
adult cardiomyocyte cell survival in the setting of simulated MI. Though it was never 
explicitly stated, it appears the authors used a full length form of JIP-1 for these studies.  
 Since it has been well documented that overexpression of JIP-1, or at least the 
JNK binding domain of JIP-1, inhibits JNK activation, we hypothesized that the blunting 
of JNK phosphorylation in neonatal cardiac myocytes by HDAC inhibition is due to 
HDAC inhibitors driving expression of JIP-1 and therefore, sequestering JNK from all of 
its upstream kinases preventing spatially favorable phosphorylation of JNK. There is very 
low basal expression of the ~100 kDa form of JIP-1 in neonatal cardiac myocytes. 
Initially, elevated expression of JIP-1 at the mRNA level was shown in the presence of 
TSA and Mocetinostat, which validated our previous PCR array results. Interestingly, 
treatment with the pan-HDAC inhibitor TSA and two class I HDAC inhibitors, 
Mocetinostat and apicidin, dramatically increased expression of the shorter ~100 kDa 
form of JIP-1 (JIP-1-SF) as well as the previously undetectable longer form (~115 kDa) 
of JIP-1 (JIP-1-LF). A time course experiment investigating how long it takes for HDAC 
inhibitors to block phosphorylation of JNK demonstrated that HDACi-inducible 
expression of JIP-1 nearly perfectly correlated with blockade of JNK phosphorylation. 
Consistent with this hypothesis was the inability of TSA to induce JIP-1 protein 
expression in the presence of the transcriptional inhibitor ActD. Additionally, we 
demonstrated that cardiac JIP-1 is dynamically regulated by the proteasome, with 




MG132. Unfortunately, subsequent experiments cast extreme doubt on our initial 
hypothesis. Overexpression of myc-tagged JIP-1-SF and FLAG-tagged JIP-1-LF failed to 
block PE-induced JNK phosphorylation. Next, shRNA-mediated knockdown of JIP-1 
failed to rescue PE-induced JNK phosphorylation in the presence of TSA. Several steps 
are being taken to further address these results, but it appears that HDACi-mediated 
expression of JIP-1 is not responsible for inhibiting the activation of cardiac JNK 
signaling.  
Materials and Methods 
Inhibitors and Agonists 
As in Chapter 2, reagents were purchased or synthesized in-house and used at the 
indicated final concentrations. HDAC inhibitors: trichostatin A (TSA) (Sigma; 200 nM), 
MGCD0103 (Selleck; 1 M), Apicidin (Enzo Life Sciences; 3 M). Phenylephrine (PE), 
MG132, and actinomycin D were purchased from Sigma and used at final concentrations 
of 10 M, 10 M, and 1 g/mL respectively. 
Cell Isolation and Culture 
Cells were prepared essentially as in Chapter 3. NRVMs were washed twice in ice-cold 
PBS (pH 7.4) prior to lysis. Cells were lysed in radioimmunoprecipitation assay buffer 
(RIPA) containing 50mM Tris (pH 8), 150 mM NaCl, 0.1% SDS, 0.5% sodium 
deoxycholate, 1% NP-40,  and HALT™ protease/phosphatase inhibitor mixture (Thermo 
Fisher). Cellular lysates were sonicated before clarification by centrifugation. 
Quantitative PCR 
RNA was isolated and qPCR was performed as previously described (265). Briefly, RNA 




converted to cDNA using the Verso cDNA Synthesis kit (Thermo Scientific). qPCR was 
performed using Absolute QPCR SYBR Green ROX mix (Thermo Scientific) on a 
StepOne qPCR instrument (Applied Biosystems). PCR primers used for: 
5’-fwd-JIP-1-CCACGCTCAACCTTTTCCC 
5’-rev-JIP-1-AGATATGTTCATGTGGAGGCG 
Endogenous control: 5’-fwd-18s-GCCGCTAGAGGTGAAATTCTTA 
Endogenous control: 5’-rev-18s-CTTTCGCTCTGGTCCGTCTT  
Relative transcript levels were assessed by measuring Ct values from a standard curve 
made from serial dilutions of cDNA.  
Immunoblotting 
Western blots were run as described in chapter 2. Proteins were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes (BioRad) and probed with antibodies for 
phospho-JNK (Cell Signaling Technology, 4668); JIP-1 (Santa Cruz Biotechnology, 
sc25267); FLAG (Sigma Aldrich, A-8592); Myc (Santa Cruz Biotechnology, sc40); 
Calnexin (Santa Cruz Biotechnology, sc11397); Total JNK (Santa Cruz Biotechnology, 
sc474); Ubiquitin (Santa Cruz Biotechnology, sc8017); Acetyl-Lysine (Cell Signaling 
Technology, 9441); cFos (Cell Signaling Technology, 4384); phospho-ASK1 (Cell 
Signaling Technology, 3765); phospho-MKK7 (Cell Signaling Technology, 4171). 
Adenoviral Production and Infection 
Adenoviruses encoding shRNA non-mammalian targeting control and shJIP-1 were 
prepared using the BLOCK-it Adenoviral RNAi Expression system (Invitrogen). A more 
detailed workflow will be described in Appendix I & II. Adenoviruses encoding JIP-1-




(Invitrogen). The PCR template for mammalian JIP-1 was purchased from Addgene 
(pCDNA3 T7 JIP1, cat# 51699). JIP-1-LF was cloned into pcDNA3.1 with an N-terminal 
FLAG tag using 5’-ClaI and 3’-EcoRI cut sites. JIP-1-SF was cloned into pcDNA3.1 
with an N-terminal myc tag using 5’-ClaI and 3’-EcoRI cut sites. Both JIP-1 isoforms 
were expressed in Cos7 cells and were recognized by JIP-1 and FLAG or myc antibodies 
at the proper molecular weight on immunoblots. Next, JIP-1-SF and JIP-1-LF were 
excised from their respective pcDNA3.1 vectors using 5’-KpnI and 3’-NotI and 
subcloned into pENTR2b. LR-recombination was then performed as per the 
manufacturer’s instructions, transferring JIP-1 genetic material from pENTR2b to pAd-
CMV-V5 DEST. Viral vectors were then transfected into 293A cells using 
polyethyleneimine (PEI). Viruses were amplified and recovered from 293A cells and 
titered using the SeaPlaque Agarose method. Adenovirus encoding FLAG-tagged MKK7 
gamma was created using a similar method. FLAG-tagged MKK7 gamma was a gift from 
Dr. Mark Dell’Acqua. PCR product was created using 5’-KpnI and 3’-XhoI primers and 
subcloned into pENTR2b. FLAG-tagged MKK7-JNK1 fusion was a gift from Dr. Lynn 
Heasley. PCR product was created using 5’-BamHI and 3’-NotI primers. The following 
workflow for adenoviral production of FLAG-MKK7 and FLAG-MKK7-JNK1 was 














RNA will be isolated using the High Pure RNA Isolation Kit (Roche) as per the 
manufacturer’s instructions.  cDNA libraries will be prepared using the NuGen Ovation 
RNA-seq Systems 1-6 for Model Organisms kit (034λ RAT) as per the manufacturer’s 
instructions.  RNA sequencing will be done by the CU-Anschutz Genomics and 
Microarray Core. 
Results 
HDACi-Mediated Blockade of JNK Activation Occurs in the Presence of Upstream 
Activators ASK1 and MKK7   
 In an effort to elucidate at what point in the JNK signaling cascade, HDAC 
inhibition exerts its antagonizing effect, we utilized adenoviral-mediated overexpression 
in neonatal rat cardiac myocytes (NRVMs) using the MAP3K ASK1 and the MAP2K 
MKK7. Immunoblotting for the phosphorylated (active) forms of members of the JNK 
signaling cascade was employed. Figure 10B shows that phospho-ASK1 was not 
antagonized by the class I HDAC inhibitor, Mocetinostat (MGCD), in NRVMs 
stimulated with PE. Additionally, phospho-MKK7 was not antagonized by MGCD. 
However, even in the presence of overexpressed ASK1 and PE stimulation, JNK 
phosphorylation was still attenuated by MGCD. Next, we overexpressed MKK7 and 
again saw no attenuation of phospho-MKK7, but robust attenuation of phospho-JNK. 
These results indicate that the antagonistic action of HDAC inhibitors on JNK activation 





Fig. 10. Canonical MAPK signaling induced by extracellular stimuli. (A) Cartoon 
depiction of JNK activation. (B) Neonatal rat ventricular myocytes (NRVMs) were 
infected with adenoviruses overexpression -galactosidase or the MAP3K, ASK1, and 
treated with vehicle or the class I HDAC inhibitor MGCD0103. (C) Procedure was the 
same as in Fig. 10B with the exception of infection with adenovirus overexpressing the 








Gain-Of-Function Chimeric MKK7-JNK1 Construct is Not Altered by HDAC 
Inhibition 
 To address the hypothesis that antagonism of JNK activation by HDAC inhibition 
occurs at the MKK7 => JNK activation step, we generated an adenovirus encoding a 
 
Fig. 11. Overexpression of gain-of-function chimeric MKK7-JNK1 fusion protein is not 
inactivated by HDAC inhibition. (A) Construct schematic. (B) NRVMs were infected 
with MKK7-JNK1 fusion protein and treated with vehicle (DMSO) or HDAC inhibitors, 
trichostatin A (TSA) or MGCD0103 (MGCD) for 24 h. 
 
fusion of an epitope-tagged direct upstream JNK kinase MKK7 and JNK1. Since the 
blockade of JNK activation by HDAC inhibitors is so robust, we hypothesized that 
HDAC inhibition would inhibit the fusion construct from phosphorylating itself. Robust 
expression of the fusion construct was achieved in NRVMs (Figure 11B); however in the 
presence of the pan-HDAC inhibitor TSA or the class I HDAC inhibitor MGCD, there 




positive control for TSA and MGCD. These results inspired us to address a different 
hypothesis for HDACi-mediated suppression of JNK activation. 
HDAC Inhibitors Modestly Stimulate JIP-1 mRNA Expression 
 Previous data from a MAPK PCR array run in our lab indicated that HDAC 
inhibitors drive expression of JIP-1 mRNA, but these data had yet to be validated. Figure 
12 depicts the results of NRVMs treated with TSA or MGCD for 48 hours. HDAC 
inhibition significantly stimulated JIP-1 mRNA 2.5 fold and 3.5 fold respectively. 
 
Fig. 12. Inhibition of HDACs modestly elevates JIP-1 mRNA expression. NRVMs were 
treated with vehicle (DMSO), TSA or MGCD for 48 h. N = 3, message signals were 
normalized to the housekeeping gene 18s. 
 
HDAC Inhibition Dramatically Stimulates Two Forms of JIP-1 
 The next logical step for assessing how HDAC inhibitors influence JIP-1 
expression is to assay JIP-1 protein levels after HDACi. A faint band of JIP-1 located 
around 100 kDa can be detected basally in NRVMs. Remarkably, once NRVMs are 
treated with TSA, not only is the faint band of JIP-1 massively upregulated, but a 




to determine which HDACs are responsible for regulating JIP-1 expression, we utilized 
the class I selective HDAC inhibitor Mocetinostat (MGCD) (Fig. 13B). Both bands of 
JIP-1 were significantly induced with MGCD in the presence or absence of hypertrophic 
agonist (PE) indicating that hypertrophic stimulus is not required for HDACi-mediated 
induction of JIP-1. Consistent with the results in Figure 13B, another structurally distinct 
HDAC inhibitor apicidin (Api) induced JIP-1 expression to an even greater degree. 
Collectively, these results indicate that class I HDACs are responsible for regulating JIP-
1 protein expression in NRVMs. 
 
Fig. 13. Dramatic induction of two forms of JIP-1 with three distinct HDAC inhibitors. 
NRVMs treated with various combinations of vehicle (DMSO), hypertrophic agonist 
phenylephrine (PE) or PE + (A) the pan-HDAC inhibitor TSA, and the class I HDAC 






HDACi-Mediated Stimulation of JIP-1 Relies Highly Upon New Gene Transcription 
 Next we sought to determine where HDAC inhibitors were influencing JIP-1 
protein expression in the lifespan of JIP-1. Using the transcriptional inhibitor 
Actinomycin D (ActinoD), we blocked transcription for 30 minutes in NRVMs prior to 
treatment with TSA. As demonstrated in Figure 14, HDAC inhibition using TSA for 8 
hours shows induction of both JIP-1-SF and JIP-1-LF, which is subsequently blocked by 
pre-treatment with ActinoD. Consistent with previous results (Fig. 5), TSA mediated 
induction of cFos was also blocked by pre-treatment with ActinoD. These results indicate 
that HDACi-mediated induction of JIP-1 requires new gene transcription. 
 
 
Fig. 14. HDACi-mediated induction of JIP-1 relies highly upon new gene transcription. 
NRVMs were pre-treated with the transcriptional inhibitor Actinomycin D (ActinoD) for 
30 min then treated with TSA for 8 h. Induction by TSA and blockade of TSA-mediated 
induction with ActinoD. cFos was used as a positive control. 
 
JIP-1 Protein Stability is Regulated by the Proteasome in NRVMs 
 Due to the low levels of JIP-1 mRNA induced by HDAC inhibition, we 
hypothesized that cardiac JIP-1 may be regulated in an additional way, separate from new 
gene transcription. To address this hypothesis we used the proteasome inhibitor MG132. 
Interestingly, treatment of NRVMs with MG132 showed an accumulation of both a 




JIP-1 isoforms was exacerbated by TSA, indicating that cardiac JIP-1 is regulated both 
transcriptionally and by the proteasome. 
 
Fig. 15. Stability of JIP-1 protein is regulated by the proteasome in NRVMs. NRVMs 
were pre-treated with TSA for 4 h, then treated with vehicle or the proteasome inhibitor 
MG132 (10 μM) for 24 h. Ubiquitin was used as a positive control for MG132. Acetyl-
lysine was used as a positive control for TSA. Calnexin was used as a loading control. 
 
Induction of JIP-1 by a pan-HDAC Inhibitor Correlates with pJNK Blockade 
 To temporally investigate when HDAC inhibitors elicit their antagonistic effects 
on JNK activation as well as at what time point JIP-1 is induced, we ran a time course 
experiment in NRVMs where we pre-treated cells with TSA for the indicated amount of 
time, treated the indicated samples with hypertrophic stimulus (PE), and probed for JNK 
activation and JIP-1 expression. Remarkably, induction of JIP-1 by TSA nearly perfectly 
correlates with inhibition of JNK activation (Fig. 16A). JIP-1 expression levels relative to 





Fig. 16. Induction of JIP-1 by a pan-HDAC inhibitor correlates with pJNK blockade. (A) 
NRVMs were pre-treated with DMSO (vehicle) or TSA for the indicated time points, 
then treated with PE for two hours prior to lysis. Immunoblotting for pJNK was used to 
assess JNK activation, total JNK was used to ensure accurate assessment of JNK 
activation as well as equal loading, JIP-1 detects both long and short forms, and acetyl-
histone H3 was used as a positive control for TSA. (B) Densitometry analysis depicts 
activation of short form JIP-1 (left panel) and long form JIP-1 (right panel) relative to 0 h 
baseline signal and averaged between both n in each treatment group. 
 
Overexpression of Epitope-Tagged Short Form and Long Form JIP-1 Does Not Block 
JNK Activation 
 Results from Figure 16 prompted us to generate adenoviruses encoding JIP-1-SF 
and JIP-1-LF, in an effort to block JNK activation by overexpression by one or both JIP-1 
isoforms. Overexpression of myc-tagged JIP-1-SF as well as FLAG-tagged JIP-1-LF 




may have modestly attenuated JNK activation. Though this attenuation is nowhere near 
the ability of TSA and class I selective HDAC inhibitors to block JNK phosphorylation. 
 
Fig. 17. Ectopic expression of short form and long form JIP-1 does not attenuate JNK 
activation. NRVMs were infected at the time of plating with beta-galactosidase (Bgal), 
short-form JIP-1 (JIP-1-SF), or long form JIP-1 (JIP-1-LF). 2x Bgal was added to 
samples labeled Bgal, and 1x Bgal was added to samples infected with JIP-1-SF and JIP-
1-LF alone to ensure equal amounts of virus were added as the JIP-1-SF + JIP-1-LF 
sample. 24 h after infection, PE was added to the indicated samples for 2 h. 
 
shRNA-mediated Knockdown of JIP-1 Does Not Rescue JNK Phosphorylation in the 
Presence of HDACi 
 To further confirm the results from Figure 17 of JIP-1’s inability to block JNK 
activation when overexpressed, adenovirus encoding shRNA directed toward JIP-1 was 
used to test the hypothesis that knockdown of JIP-1 would rescue HDACi-mediated 
attenuation of JNK phosphorylation. In the presence of an adenovirus encoding a non-
mammalian targeting shRNA (shControl), JIP-1 protein expression was robustly 
activated and JNK phosphorylation was attenuated in the PE+TSA treatment group. 




knocked down in the PE+TSA treatment group. These results strongly indicate that 
HDACi-mediated induction of JIP-1 is not responsible for the ability of HDAC inhibitors 
to antagonize JNK activation. 
 
Fig. 18. Activation of JNK is not rescued under HDAC inhibition when JIP-1 is depleted 
in NRVMs. NRVMs were infected at the time of plating with shRNAs encoding either a 
non-mammalian targeting sequence (shControl) or a JIP-1 targeting sequence (shJIP-1). 
36 h after infection, samples were treated with either DMSO (vehicle) or TSA as 




 The wide reach of cellular lysine acetylation has been proposed to be second only 
to serine/threonine/tyrosine phosphorylation in the number of experimentally observed 
PTMs by category (272). Subsequent quantitative proteomic experiments have uncovered 
thousands of additional lysine acetylation sites (139,141,142). Our lab is motivated by 
these studies and uses them as tools to discover novel roles for HDAC inhibition in the 
context of cardiac biology. We have long been privy to the antagonistic role of HDAC 
inhibition on cardiac JNK signaling, but have yet to elucidate the mechanism. The 




primary goal. Yet, as the results from the subsequent experiments came to fruition, the 
new goal pivoted to elucidating the role of HDACi-mediated induction of JIP-1 in cardiac 
myocytes.  
 Impressively, the potent antagonistic effect of HDACi on JNK activation was not 
thwarted by overexpression of upstream MAP3K (ASK1) or MAP2K (MKK7) (Fig.10). 
These results led us to hypothesize that maybe acetylation of JNK itself was inhibiting 
the ability of activated MKK7 to phosphorylated JNK, as JNK1 and JNK3 were found in 
the acetylome (Table 7). With this hypothesis in mind, an adenovirus encoding a 
chimeric MKK7-JNK1 fusion construct was generated. We reasoned that the robust 
attenuation of phosphorylated JNK by HDACi would also attenuate activation of the 
fusion construct. Unfortunately, HDACi with TSA or Mocetinostat had no effect on the 
activation of JNK by the attached, constitutively activated MKK7 (Fig. 11). Our 
phospho-JNK antibodies recognize the conserved TxY motif on all isoforms of JNK, so 
there are several potential explanations for HDACi being unable to attenuate activation of 
the fusion construct: perhaps the JNK1 portion of the fusion construct is unable to be 
acetylated by HATs, the specific combination of MAP2K-MAPK isoforms in the fusion 
construct was inadequate, the fusion construct is unable to bind necessary inhibitory 
scaffold proteins, or the fusion construct may be localized to an area of the cell where the 
necessary inactivation machinery is not present. Several of these questions still need to be 
addressed and we decided to validate our findings from our MAPK PCR array to further 
address this hypothesis. 
Fortunately, we have had great success in the past validating data from PCR 




different. We describe the 2.5 and 3.5 fold induction of JIP-1 mRNA by TSA and 
Mocetinostat as modest due to the robust induction of JIP-1-SF and JIP-1-LF at the 
protein level by three distinct HDAC inhibitors (Fig. 12 & 13). Though mRNA 
expression levels do not always correlate with relative protein expression, we found the 
sheer degree of elevation in protein expression of JIP-1 findings perplexing and prompted 
us to run mechanistic studies investigating why the protein levels of JIP-1 are so robustly 
elevated with HDACi. 
Indeed as canonical HDAC inhibitory actions would suggest, pre-treatment of 
NRVMs with ActinoD significantly blunted induction of both JIP-1-SF and JIP-1-LF, 
indicating that elevated JIP-1 expression in the presence of HDACi is transcriptionally 
regulated (Fig. 14). Adding to these findings, we hypothesized that perhaps JIP-1 protein 
is regulated at yet another level due to the modest increase in JIP-1 mRNA. To address 
this hypothesis we treated NRVMs with the proteasome inhibitor MG132, and noticed a 
modest accumulation of both JIP-1 isoforms as well as a shift in the gel, perhaps 
indicative of a post-translational modification of JIP-1 (Fig. 15). Interestingly, NRVMs 
pre-treated with MG132 followed by TSA showed a synergistic induction of JIP-1. 
Further emphasis on this observation should be considered due to the paradoxically 
protective effects of proteasome inhibitors targeting selective proteasome complexes in 
HF (273).    
Robust JIP-1 induction led us to investigate the temporal actions of HDAC 
inhibition antagonizing JNK activation and inducing JIP-1-SF and JIP-1-LF protein 
expression. TSA was chosen due to its rapid onset of inhibiting HDACs, allowing us to 




JNK appeared to increase up to 4 hours of pre-treatment with TSA, followed by 
progressive attenuation of JNK activation at 8 hours and a phospho-JNK signal below 
baseline at 24 and 48 hours of TSA pre-treatment. These actions appeared to nearly 
perfectly correlate with JIP-1 expression. As JIP-1 protein levels increased, there was a 
modest enhancement of active JNK, perhaps signifying an optimal level of JIP-1 for 
facilitating stoichiometric organization of MAP3Ks, MKK7 and JNK. This was followed 
by JNK attenuation when JIP-1 was vastly above baseline levels, perhaps indicating that 
at this expression level of JIP-1, binding partners necessary for optimal JNK activation 
were sequestered away due to super-stoichiometric ratios of JIP-1 to the JNK signaling 
cascade. We addressed this hypothesis by generating adenoviruses encoding JIP-1-SF 
and JIP-1-LF using the well-studied sequence of JIP-1-LF from Roger Davis’ JIP-1 
studies (274,275). We hypothesized that both observed JIP-1 isoforms were in fact JIP-1 
due to lentiviral-mediated knockdown of both isoforms in the presence of TSA (data not 
shown). Also, we found a paper of the molecular cloning of mammalian JIP-1 describing 
a transcript of JIP-1 that started at methionine-101 (276). The missing 100 amino acids of 
JIP-1 appeared to correlate with the predicted size of what we call JIP-1-SF, and to our 
delight, ran at the same molecular weight as JIP-1-SF in NRVMs (data not shown). 
Unfortunately, overexpression of JIP-1-SF, JIP-1-LF and the two ectopic JIP-1 isoforms 
in tandem did not blunt JNK activation in NRVMs (Fig. 17).  
To follow up on the results from figure 17, we knocked down the JIP-1 isoforms 
in the presence of HDACi and probed for JNK activation in NRVMs. Empirical 
observations from our laboratory demonstrate that while utilization of lentivirus to 




sequences, NRVMs do not tolerate lentivirus well and rarely exhibit typical physiological 
responses to PE. Therefore, we took the lentiviral shRNA sequences targeting JIP-1 and 
inserted them into adenoviral vectors. Confirming the previous findings, shRNA-
mediated knockdown of both isoforms of JIP-1 was unable to rescue HDACi-mediated 
suppression of JNK activation (Fig. 18). 
These results indicate that JIP-1 is not performing its canonical role in NRVMs, 
and due to observed morphological changes is likely performing a yet to be determined 
molecular function. The next steps in this project will be to determine what that unknown 
function is.   
Conclusions 
 The canonical role of JIP-1 as eliciting antagonistic effects on cardiac JNK 
signaling proved not to be the case in our hands. We explicitly demonstrate the inability 
of two JIP-1 isoforms to inhibit JNK activation when overexpressed in cultured cardiac 
myocytes, as well as the inability of JNK activation to be rescued in the presence of 
HDACi when both isoforms of JIP-1 are knocked down by shRNA. However, we do 
believe that there is a yet to be discovered role for HDACi-mediated JIP-1 induction in 
cardiac myocytes, as morphology appears to be different in the presence or absence of 
JIP-1 in HDACi treated cardiac myocytes (unpublished observations). The measures of 
which we will use to discover this function of HDACi-mediated induction of JIP-1 will 
be described in the subsequent section. 
Limitations and Future Directions 
A potential limitation to these studies is that we only addressed one member of 




ability to dimerize and heterodimerize (277,278). Data from our MAPK PCR array 
indicated, albeit unclearly, that JIP-2 mRNA expression was also elevated in NRVMs. 
Also, we have seen from qPCR results that JIP-2 expression is elevated when JIP-1 is 
knocked down, suggesting that these JIP isoforms may serve redundant functions in 
cardiac myocytes as well as potentially facilitating JNK activation in the absence of one 
another.  
Our next step in determining the role of HDACi-mediated induction of JIP-1 is 
through RNA sequencing (RNAseq). The immunoblot in Figure 19 confirms the quality 
of our samples for investigating the role of JIP-1 in HDAC inhibitor treated cardiac 
myocytes. We will use an n=2 for each of the four indicated samples in order to be 
confident that our RNAseq results are real. From there our lab will look at the differences 
in transcript levels from these samples in order to elucidate the consequences of knocking 
down JIP-1 in cardiac myocytes undergoing hypertrophic stimuli (PE) and blunting of 
hypertrophy with HDAC inhibition (PE+TSA). 
 
Fig. 19. Efficient knockdown of JIP-1 in NRVMs for RNA sequencing. NRVMs were 
infected at 50 MOI (Multiplicity of Infection, or ratio of infectious viral particles per cell) 
with adenovirus encoding an shRNA non-mammalian targeting sequence (shControl) or 
with an shRNA encoding a JIP-1 targeting sequence at the time of plating. 40 h after 
infection, samples were treated with vehicle (DMSO) or TSA for 8 h prior to lysis. 





Additionally, chromatin-immunoprecipitation followed by DNA sequencing 
(ChIPseq) data from our lab indicate that in the absence of an HDAC inhibitor, RNA 
polymerase II (RNA pol II) which is commonly found at actively transcribed regions of 
the genome peaks at exon 3 in the rat JIP-1 promoter (Fig. 20). This observation is 
consistent with the presence of only JIP-1-SF at baseline, without HDACi in NRVMs. It 
will be interesting to determine if more RNA pol II clusters would occur at exon 3 and at 
exon 1 after HDACi in the future. 
 
Fig. 20. Chromatin-Immunoprecipitation Sequencing analysis (ChIP-Seq) of the JIP-1
promoter. Antibodies targeting Bromodomain containing Protein 4 (BRD4) and RNA 
Polymerase II (PolII) were used to selectively enrich DNA sequences bound by these 
protein targets. Sequencing analysis of the resulting immuno-enriched DNA fragments 
are represented by the black bars above. BRD4 and PolII were targeted as baseline or in 













HISTONE DEACETYLASES: POTENTIAL THERAPEUTIC TARGET IN 
SINGLE VENTRICLE HEART DISEASE 
Introduction 
Right ventricular hypertrophy (RVH) and pulmonary hypertension are common 
sequelae in pediatric patients with various forms of congenital heart disease. On the 
severe end of the spectrum, are children with single ventricle heart disease (SV), 
especially those with a single right ventricle (RV) such as hypoplastic left heart 
syndrome. SV is a rare but important form of hypoxic congenital heart disease that is 
fatal without intervention (279). Current treatment strategies for infants born with SV 
include a 3-stage surgical palliation (Table 3) or primary heart transplantation. Primary 
heart transplant is significantly limited by donor availability. Though there have been 
advancements in the perioperative and surgical approaches for SV, 32% of those 
managed with surgical palliation die or are transplanted prior to 1 year of age (280), 
underscoring the need for ongoing efforts to improve outcomes. Failure of the single RV 
is a common cause of death and indication for transplant in the SV population. 
Unfortunately, there are no proven therapies for single RV failure.  
 Histone deacetylases (HDACs) are epigenetic enzymes that function canonically 
through removal of acetyl post-translational modifications of ε–amino groups on lysine 
residues. The 18 mammalian HDACs are categorized into 4 classes: class I (HDACs 1, 2, 
3, 8), class IIa (HDACs 4, 5, 7, 9), class IIb (HDACs 6, 10), class III (SIRT1-7), and 
class IV (HDAC11). Class III HDACs are also known as sirtuins and use NAD+ as a 




protective in the setting of HF due to their ability to bind to and inhibit the transcriptional 
activity of myocyte enhancer factor 2 (MEF2) (281). Elevated catalytic activity of 
sirtuins is thought to be beneficial in failing hearts (282), whereas elevated catalytic 
activity of class I and IIb HDACs is thought to be maladaptive (158,283).  
 Two HDAC inhibitors, Vorinostat (suberoylanilide hydroxamic acid, ZolinzaTM) 
and Romidepsin (IstodaxTM) are FDA approved to treat cutaneous T-cell lymphoma. 
Many other HDAC inhibitors are currently in clinical trials, investigating efficacy in a 
variety of diseases (https://clinicaltrials.gov/ct2/results?term=histone+deacetylase+ 
inhibitor&Search=Search). Inhibition of HDACs has beneficial effects in pre-clinical 
models of HF, reduces cardiac hypertrophy (284) and fibrosis (285), and suppresses the 
fetal gene program associated with cardiac remodeling (286). These findings make 
HDACs a promising therapeutic target for the treatment of human HF (287). We sought 
to measure HDAC catalytic activity and HDAC protein expression in the myocardium of 
SV patients, as well as develop an animal model that accurately recapitulates the 
myocardial adaptations associated with this disease process. 
 The purpose of this study was to examine the protein expression and catalytic 
activity of HDACs in pediatric SV patients with a single RV, and develop a pediatric 
animal model for use in pre-clinical study and pharmacotherapeutic development. We 
hypothesized that pediatric SV patients would exhibit elevated HDAC catalytic activity, 
and that hypoxia would result in elevated HDAC catalytic activity in neonatal rat RV. 
This study is the first to report elevated HDAC catalytic activity and HDAC protein 
expression in a pediatric heart disease population and development of an animal model 




Materials and Methods 
Human Tissue Procurement 
This study used heart tissue samples from pediatric patients (<18 years of age) that 
donated their hearts to the University of Colorado Institutional Review Board-approved 
pediatric heart tissue bank (informed consent is obtained for all patients). Patients 
included male and females of all races and ethnic background undergoing heart 
transplantation at Children’s Hospital Colorado. Nonfailing (NF) control hearts were 
obtained from pediatric donors (<18 years of age) with structurally normal hearts and 
normal heart function whose hearts could not be placed for technical reasons, usually size 
or blood type mismatch. SV tissue was obtained from explanted hearts of patients with 
single ventricle physiology and a morphologic single RV. Patients with a single LV or 
indeterminate morphology of the single ventricle were excluded. All heart tissue was 
rapidly flash frozen in the operating room immediately after removal from the subject. A 
detailed description of patients included in this study is outlined in Table 6. 
Histone Deacetylase Catalytic Activity Assay 
Measurement of HDAC catalytic activity was performed as previously described (288). 
Reagents were purchased from indicated vendors. HDAC inhibitor, Trichostatin A (TSA; 
Sigma) diluted in dimethylsulfoxide (DMSO). Synthetic HDAC substrates: class I HDAC 
substrate (custom synthesis by Genscript), class IIa HDAC substrate (I-1985; Bachem), 
class I/IIb HDAC substrate (I-1875; Bachem). Trypsin, Triton X-100, and DMSO were 
obtained from Sigma. 7-Amino-4-methylcoumarin (AMC; Alfa Aesar).  
Frozen explants from human pediatric RV were prepared in PBS (pH 7.4) containing 




(ThermoFisher) using a Bullet Blender homogenizer (Next Advance). Protein 
concentrations were determined by BCA Protein Assay Kit (ThermoFisher). Incubation 
of tissue lysates with class selective HDAC substrates results in a cleavable AMC 
product. AMC fluorescence was measured using a BioTeK Synergy 2 plate reader, with 
excitation and emission filters of 360 nm and 460 nm. Background fluorescence from 
buffer blanks were subtracted from raw signals and data were normalized as needed using 
appropriate controls.   
Immunoblotting 
Immunoblotting was performed as previously described (289). Briefly, pediatric human 
and neonatal rat RV homogenates were prepared and concentrations quantified as above 
for HDAC catalytic activity assay. Proteins were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes (BioRad) and probed with antibodies for HDAC1 (Cell 
Signaling Technology, 5356), HDAC2 (Cell Signaling Technology, 5113), HDAC3 (Cell 
Signaling Technology, 3949), HDAC4 (Cell Signaling Technology, 5392), HDAC5 (Cell 
Signaling Technology, 2082), HDAC6 (Santa Cruz Biotechnology, 11420), HDAC7 
(Cell Signaling Technology, 2882), Calnexin (Santa Cruz Biotechnology, 11397). 
Animal model 
The pediatric neonatal rat RV hypertrophy model was adapted from a previous study 
(290). Timed-pregnant E17 Sprague Dawley rats were obtained from Charles River 
Laboratories. Rat mother’s birthed their litters at Denver altitude and equilibrated for one 
day. Post-natal day 1 normoxic animals were placed in a hypobaric chamber simulating 
sea level altitude (21% oxygen), while post-natal day 1 hypoxic animals were placed in a 




were anesthetized with isoflurane and sacrificed by thoracotomy. Hearts were flushed 
with saline through the aorta, atria were removed, and right ventricles were carefully 
separated from left ventricle and septum, prior to flash freezing in liquid nitrogen.  
Hemodynamics 
Echocardiographic analysis was performed using a Vevo2100 system equipped with 
MS400 18-38 MHz transducer (VisualSonics), as previously described (158).  
Real-time Polymerase Chain Reaction 
Real-time polymerase chain (RT-PCR) reactions were performed as previously described 
(291). Total RNA was extracted by mirVana kit (Ambion, Austin, TX), RNA was reverse 
transcribed into complementary DNA using I-script (Bio-Rad, Hercules, CA), and Power 
SYBR Green PCR Master Mix was (Applied Biosystems/Life Technologies, Carlsbad, 
CA) were used in the RT-PCR reactions. Reactions were performed using the ABI 7300 
system. Primer sequences are indicated below: 
ANFμ Forward 5’- gcgaaggtcaagctgctt; Reverse 5’- ctgggctccaatcctgtcaat 
BNPμ Forward 5’- ggtgctgccccagatgatt; Reverse 5’- ggtgctgccccagatgatt 
Serca2aμ Forward 5’- ggccagatcgcgctaca; Reverse 5’- gggccaattagagagcaggttt 
Data Analysis 
GraphPad Prism software was used to generate graphs and analyze data. Where indicated, 
student’s T-test with Welch’s correction or ANOVA with Bonferroni’s post-test (p<0.05) 








 The mean age of the NF controls was 9.23 years (SEM=3.76, SD=4.74) with 17% 
female. The mean age of the SV group was 0.15 years (SEM=0.06, SD=0.05) with 17% 
female. The indication for transplantation for the SV group is outlined in Table 6 and 
varies from those undergoing primary transplant (listed for transplant shortly after birth 
prior to surgical palliation), to those that suffered surgical palliation failure.  
Table 6: Single ventricle and non-failing patient characteristics. NF = non-failing; SV = 
single ventricle; PDE = phosphodiesterase; ACEI = angiotensin converting enzyme 
inhibitor; BB = beta-blocker; NA = not available; PGE – prostaglandin E1 infusion to 
maintain ductus arteriosus patency; PDA = patent ductus arteriosus. Inotropes include 











































HDAC Catalytic Activity is Elevated in Pediatric Single-Ventricle Patients 
The relative levels of HDAC catalytic activity in the human heart are currently 
unknown. To investigate whether pediatric SV patients had elevated HDAC catalytic 
activity, RV lysates from pediatric NF controls and pediatric SV patients were incubated 
with HDAC class specific small molecule substrates (Figure 21B).  Elevated HDAC 
catalytic activity was observed for each HDAC class specific substrate in the RV of SV 
patients relative to NF control RV. The largest fold increase was observed using the class 
IIb substrate (~3.5 fold), followed by a 2-fold increase in class I HDAC catalytic activity 
and a modest, but statistically significant increase in class IIa HDAC catalytic activity. 
These observations are consistent with reported increases in HDAC catalytic activity in 
the hearts of spontaneously hypertensive rats (292) and a murine model of ischemia-
reperfusion (293). 
 
Fig. 21. HDAC Catalytic Activity is Elevated in Remodeled Pediatric RVs. (A) Left 
panel, histone deacetylase (HDAC) and histone acetyltransferase (HAT) mechanism of 
action. Right panel, 18 mammalian HDACs organized by class. Black deacetylase 
domains denote Zn2+ dependency. (B) RV tissue from normal and hypertrophic SV hearts 
was homogenized in a mild lysis buffer and incubated with HDAC class I, IIa, and IIb 
specific substrates. All classes of HDACs displayed elevated catalytic activity relative to 
control. Results are displayed as the mean with standard error (error bars) and statistical 







Individual HDAC Isoform Protein Expression are Elevated in Pediatric Single-
Ventricle Patients 
Since all classes of HDACs measured exhibited elevated catalytic activity in RVs 
of SV patients, we investigated whether the protein expression of HDACs belonging to 
class I, IIa and IIb were elevated. Protein expression of HDAC1-7 was measured by 
immunoblotting (Figure 22) and quantified by normalization to a house-keeping protein, 
calnexin (Figure 23). 
 
Fig. 22. Pediatric RV from SV Patients Display Elevated HDAC Protein Expression. 
Immunoblot analysis from the same samples used for the HDAC catalytic activity assay 
in Fig. 21b were probed for class I HDACs (HDAC1-3), class IIa HDACs (HDAC4, 5, 7) 
and the class IIb HDAC6.  
 
 Interestingly, expression of class I HDACs -1, -2, and -3 was elevated and 
reached statistical significance in SV patient compared to NF controls. Expression of 






Fig. 23. Densitometry Analysis of SV RV HDAC Protein Expression. Protein expression 
from all HDAC isoforms was significantly elevated or trending higher in the SV RVs 




elevated to a statistically significant level in SV patient RVs. The class IIb HDAC6 was 
only slightly more elevated in SV patients when normalized to calnexin compared to NF  
(Figure 23), which was surprising, considering class IIb HDAC catalytic activity was 3-
fold higher in SV patients compared to controls.   
Echocardiographic Analysis of Hypoxic Neonatal Rats Demonstrates Right 
Ventricular Hypertrophy and Pulmonary Hypertension 
RVH and failure is a common phenotype in pediatric patients with pulmonary 
hypertension and various congenital heart lesions including SV. In an effort to re-create 
elements of pediatric RVH, neonatal rats were placed in a hypobaric chamber simulating 
18,000 feet in elevation and 10% O2 for seven days. Control animals were simultaneously 
housed at sea level altitude and 21% O2 for seven days (Figure 24). We decided to use 
neonatal rats for two reasons: 1) in previous experiments run by our lab, C57BL/6 mice 
were largely resistant to cardiopulmonary remodeling when exposed to hypobaric 
hypoxia compared to neonatal rats (unpublished data). 2) In order for us to develop a 
non-invasive translational animal model, we needed to utilize echocardiography. 
Neonatal rats are much larger than neonatal mice, and our transducers were not small 
enough to be able to consistently echo neonatal mice. 
To assess functional hemodynamics in the neonatal rats, we performed 
echocardiographic analysis on the right ventricle and pulmonary artery. The free wall of 
the right ventricle was measured in systole and diastole. There was a significant increase 
in free wall thickness in both systole and diastole as quantified by M-mode images of the 




echocardiographic finding in SV as a consequence of the increased afterload inherent to 
single ventricle physiology. 
Pulmonary artery blood flow was assessed using color doppler and pulse-wave 
doppler. We found a significant decrease in pulmonary artery acceleration time (PAAT) 
in the hypoxic neonatal rats compared to sea level controls. Pulmonary valve peak 
velocity (PVPV) and pulmonary valve velocity-time integral (PV VTI) were also 
significantly decreased (Figure 24). PAAT, PVPV and PV VTI are common, well-
accepted measurements in the human clinical setting for patients with pulmonary 
hypertension (294,295). These findings confirm the presence of pulmonary hypertension 






Fig. 24. Echocardiographic Analysis of Right Ventricular Hypertrophy and Pulmonary 
Hypertension Present in Hypoxic Neonatal Rats. (A) Study design. (B) Right ventricular 
hypertrophy as assessed by M-mode. RV free wall is indicated by blue bars and 
quantified in the right panel. (C) Pulmonary hypertension as assessed by color doppler 
and pulse-wave doppler of the pulmonary artery. Pulmonary artery acceleration time 
(PAAT) and pulmonary valve velocity-time integral (VTI) are indicated by yellow 
arrows. PAAT, VTI and pulmonary valve peak velocity are quantified in the panels on 
the right. (D) B-mode parasternal short axis view of the RV and LV chambers. 
Representative images of the RV and LV chambers and interventricular septum (septum) 
are outlined in blue. Results are presented as the mean with standard error (error bars) 








Heart chamber remodeling was visualized by B-mode parasternal short axis 
evaluation, demonstrating septal wall flattening and chamber dilation in the right 
ventricle of the hypoxic neonatal rats (Figure 24). This septal wall flattening occurred in 
100% of the hypoxic animals echoed, and in none of the sea level animals. 
Morphometric RV Analysis, Gene Expression and HDAC Catalytic Activity in Hypoxic 
Neonatal Rats are Consistent with Pathologic Remodeling 
 To further quantify the degree of RV hypertrophy in the hypoxic animals, we 
measured the weights of the RV and the left ventricle (LV) plus interventricular septum 
(S), and compared the ratio of RV/LV+S. After 7 days of hypobaric hypoxia, the ratio of 
RV/LV+S was 1.5 fold higher than in the sea level control animals (Figure 25). These 
data indicate that hypertrophic RV growth is a consequence of the hypoxic conditions. 
 Myocardial failure in humans is characterized by recapitulation of a "fetal" gene 
program as embryonically-expressed genes are reactivated (3). This gene program is 
indicative of ventricular remodeling and is typified by increases in beta-myosin heavy 
chain (b-MHC), B-type natriuretic peptide (BNP) and atrial natriuretic peptide (ANP), 
and coordinate decreases in alpha-myosin heavy chain (a-MHC) and sarcoplasmic 
reticulum calcium-ATPase 2a (SERCA2a). Messenger RNA (mRNA) expression levels 
of ANP and BNP were elevated 3-fold and 5-fold respectively while SERCA2a 
expression was significantly attenuated in the hypoxic animals compared to sea level 




Fig. 25. Morphometric RV Analysis, Gene Expression and HDAC Catalytic Activity in 
Hypoxic Neonatal Rats are Consistent with Pathologic Remodeling. (A) Hearts from 
neonatal rats were flushed with saline, RV and LV + septum (S) were carefully separated 
and weighed. (B) Fetal gene markers, mRNA transcripts: brain natriuretic peptide (BNP), 
atrial natriuretic factor (ANF), and sarcoplasmic reticulum calcium ATPase 2a (Serca) 
were measured in RV tissue of normoxic and hypoxic neonatal rats. (C) Neonatal rat RVs 
were flushed, homogenized and incubated with HDAC class selective substrates as in 
Fig. 21b. Results are presented as the mean with standard error (error bars) and statistics 










HDAC catalytic activity was then measured in the RVs of sea level and hypoxic 
neonatal rats. Interestingly, significant increases in class I HDAC and class IIb HDAC 
catalytic activity were observed in hypoxic RVs, which was consistent with pediatric 
SVs. However, unlike pediatric SVs, there was no difference in class IIa HDAC catalytic 
activity in hypoxic RVs (Figure 25). 
HDAC Protein Expression in Hypoxic Neonatal Rats is Consistent with Human SV 
Patients 
 Due to the significant elevations in catalytic activity of class I and class IIb 
HDACs in the hypoxic neonatal rat RV, protein expression levels of class I HDACs (-1, -
2, -3) and the class IIb HDAC6 were assayed by immunoblotting. Again, consistent with 
the pediatric SV data, the level of HDAC2 was significantly elevated in hypoxic neonatal 
rat RVs (Figure 26). 
 
Fig. 26. Elevated Levels of Class I and Class IIb HDAC Protein Expression in Hypoxic 
Neonatal Rat RV is Consistent with RV from SV Patients. Since class I and class IIb 
HDAC catalytic activity were elevated as shown in Fig. 25c, neonatal rat RVs were 
homogenized, subjected to immunoblotting and probed with antibodies targeting class I 




HDAC1 and HDAC3 expression levels were significantly elevated in pediatric 
SV RVs and demonstrated a trending increase in hypoxic neonatal rat RVs. HDAC6 
protein expression was significantly elevated in hypoxic neonatal rat RVs, consistent with 
the trending increase in HDAC6 protein expression in pediatric SV RVs (Fig. 27).   
 
Fig. 27. Quantification of HDAC Expression in Hypoxic Rat RVs. Densitometry analysis 
normalized to calnexin loading control showed statistically significant increases in 
HDAC2 and HDAC6 with HDAC1 and HDAC3 trending upward in hypoxic RV 
compared to normoxic RV. Results are presented as the mean with standard error (error 
bars) and statistics were performed with student’s t-test (p<0.05). 
 
Discussion 
No effective available pharmacotherapy to prevent or treat myocardial failure in 
patients with single-ventricle physiology exists, underscoring the dire need for research 
and development of targeted therapies to treat complex congenital heart lesions (73). 
Treatment of adult HF has dramatically advanced over the past several decades, yet many 
of the drugs used to treat adult HF have not been proven to be beneficial in treating 
pediatric HF (296). Part of the challenge lies in the fact that pediatric HF is a much more 




ranges from idiopathic dilated cardiomyopathy (IDC) as the leading indication for heart 
transplant in children to single ventricle heart disease, the leading indication for 
transplant in infants  (297). There are inherent differences in myocardial adaptation 
including gene, protein, adrenergic receptor and microRNA expression, protein 
phosphorylation and enzyme activity in children with IDC and SV compared to adults 
(291,298-300). In addition, children are a vulnerable population limiting the ability to 
perform the invasive studies that have been so useful in advancing the care of adults with 
HF. Therefore, this study was designed to identify a novel therapeutic target in the 
pediatric SV population and develop an animal model with potential to facilitate 
mechanistic study as well as drug development relevant to this unique population. 
The molecular mechanisms of HDACs in pressure-overload induced LV 
hypertrophy, myocardial interstitial fibrosis; cardiac inflammation, pulmonary 
hypertension and RV remodeling are only beginning to be understood (301-303). HDAC 
inhibition is effective in improving HF symptoms in animal models of spontaneously 
hypertensive rats (292), mouse models of myocardial infarction/ischemia-reperfusion 
(293) and an angiotensin II-infusion model of cardiac fibrosis (285). Consistent with our 
hypothesis, the class I HDAC inhibitor apicidin attenuated hypoxia-induced RVH and 
pulmonary vascular remodeling in neonatal mice (304). A recent proteomic study using 
19 different HDAC inhibitors in three different human cell lines demonstrated the 
complexity of individual small molecule effects on the acetylome, with differential 
effects on the magnitude of acetylation signal and specific acetylation targets between 
compounds (305). Due to these findings, selection of the class of HDAC inhibitor and 




In combination with our previously described abnormalities in the -AR system 
(291), elevated HDAC catalytic activity and expression in the RV of children with SV 
suggests that SV hearts are on a one-way path toward failure, making therapeutic 
intervention with HDAC inhibitors an intriguing concept. Consistent with the molecular 
findings, clinically the single RV does not tolerate chronic pressure overload indefinitely 
and invariably ventricular failure ensues in these patients. Theoretically, HDAC 
inhibition could abrogate the pathologic remodeling process and the failing phenotype, 
extending the life expectancy of the single RV. 
While prenatal models of SV exist (306-308), a postnatal animal model is not 
feasible due to complexities of maintaining the SV circulation after birth. Therefore, we 
developed a hypoxic neonatal rat model that reasonably recapitulates many of the 
echocardiographic and molecular signatures of pediatric SV. Children born with SV are 
hypoxic until the 3rd stage of surgical palliation (Fontan) is completed at 2-5 years of age 
and systemic afterload on the RV is present throughout their lifespan with hypertrophy 
essentially a universal finding. Hypoxia in neonatal rats results in pulmonary 
hypertension and RVH by echocardiographic and morphometric assessment, altered 
myocardial gene expression with partial recapitulation of the fetal gene program, elevated 
HDAC class I and IIb activity and elevated HDAC Class I (HDAC2, trends toward 
increasing HDACs -1 and -3) and IIb (HDAC6) protein. From both a physiologic and 
molecular perspective the hypoxic neonatal rat model has similarities to the human SV 
condition that support its use for future mechanistic studies of RV remodeling as well as 
for therapeutic development. The use of echocardiography in this model not only 




and failure are not uncommon in the pediatric cardiovascular disease population and this 
model has potential to affect a myriad of populations beyond SV. Pulmonary 
hypertension, intrinsic lung disease, various forms of biventricular congenital heart 
disease (e.g. tetralogy of Fallot, Ebstein’s anomaly) also result in pediatric RV 
remodeling and failure.  
There are important limitations to this study. The tissue bank based aspect of this 
study is inherently cross-sectional and proof of mechanistic associations based on our 
results is not possible. Due to the rarity of this form of congenital heart disease, and thus 
the limited tissue available for study, it is not possible for us to determine the influence of 
age, prior surgical procedures, medications or clinical status of the patient on our 
findings. We recognize that we have not developed a rodent model of SV, however many 
of the findings in this study show consistent changes in phenotype and molecular 
signatures of hypoxic neonatal rats and SV patients versus their respective controls. This 
model could be used as a platform for the development of not only HDAC inhibitors, but 
other pharmacotherapeutics for the treatment of congenital heart disease. 
Conclusions 
In conclusion, though HDACs are ubiquitously expressed and are essential 
enzymes, HDAC inhibitors are surprisingly well tolerated (309-311). Side-effects such as 
nausea, fatigue, transient thrombocytopenia and myelosuppression has been observed in 
cancer patients treated with high doses of HDAC inhibitors. There is an evolving body of 
literature suggesting that HDAC-inhibition has value for the treatment of adult 
cardiovascular diseases. The results of this study demonstrate that HDACs could 




rare disease in a vulnerable population the hypoxic neonatal rat represents a reasonable 
platform for extending this line of investigation and exploring the utility of HDAC class 
specific inhibition in preventing or limiting pathologic RV remodeling. 
Future Directions 
 The next key steps are to test various small molecule compounds in this pediatric 
rat model of RV remodeling. We provide strong evidence for the aberrant expression of 
various HDAC isoforms, as well as evidence for elevated HDAC catalytic activity that 
accurately translates from our pediatric RV remodeling pre-clinical studies to a human 
pediatric RV remodeling syndrome. We hypothesize that HDAC inhibitors tested in our 
pre-clinical animal model will alleviate RV remodeling symptoms, and stabilize these 
animals in the presence of hypoxic stress. However, as alluded to above, not all HDAC 
inhibitors elicit equal molecular actions, so careful consideration should be taken when 
selecting which HDAC inhibitor to use in this model. Our lab has shown remarkable 
efficacy and tolerability of the pan-HDAC inhibitor ITF2357 in other models of HF.
Also, as mentioned above, another group demonstrated efficacy of the class I HDAC 
inhibitor Apicidin in a mouse model of hypobaric hypoxia. These would be two 
promising candidates to begin efficacy studies.  
 Though we have shown molecular evidence for the use of HDAC inhibitors in 
this model, we do not want to limit efficacy studies to HDAC inhibitors alone. Our 
colleagues have demonstrated evidence for efficacy of the phosphodiesterase 3 inhibitor 
(PDE3i) milrinone in pediatric HF (300). PDE3 inhibitors as well as other promising 






SUMMARY, FUTURE DIRECTIONS AND PERSPECTIVES 
Summary 
 We have known the therapeutic potential of HDAC inhibitors for the treatment of 
HF for years, yet the molecular mechanisms as to why HDAC inhibitors are so effective 
in pre-clinical models of HF remain poorly understood. This may be due to the fact that 
thousands of proteins have been identified to harbor acetylation sites by recent proteomic 
studies. These data suggest that there are potentially vast cell-wide effects, via increasing 
acetylation of histone and non-histone proteins that cooperate for beneficial effects of 
HDAC inhibition in the setting of HF. The goals of this dissertation were to identify 
novel molecular mechanisms illuminating reasons for how HDAC inhibition is 
efficacious in the context of HF, and how HDAC inhibition alters cardiomyocyte 
signaling. Additionally, I sought to develop a translational HF model for an underserved 
pediatric patient population in an effort to give credence to the use of HDAC inhibitors as 
a bridge therapy to transplant in pediatric patients with single ventricle physiology. 
 In Chapter 2, I discussed the paradoxical discovery of HDAC inhibitors as potent 
stimulators of cardiac protein SUMO-1-ylation. This proved to be an exciting finding 
because overexpression of SUMO-1 in the heart was demonstrated to be protective in 
multiple models of HF. Using our arsenal of class and isoform-selective HDAC 
inhibitors, we were able to narrow down the HDAC isoforms involved in stimulating 
SUMO-1-ylation to HDAC1 or HDAC2 using the HDAC1/2 selective inhibitor biaryl-60 
(BA60) (Fig. 2B & 2C). Further confirming the role of one of these HDAC isoforms was 




clearly demonstrates increased SUMO-1 conjugates upon knockdown of HDAC2, 
implicating that HDAC2 is an endogenous inhibitor of cardiac SUMO-1-ylation. Next, in 
an effort to explain why the majority of substrates with increased SUMO-1 modification 
run at high molecular weights, we investigated whether or not these SUMO-1 substrates 
were also attached chains of SUMO-2/3 or ubiquitin. Subsequent co-immunoprecipitation 
studies determined that the SUMO-1 substrates were not modifying substrates also 
attached to SUMO-2/3 or ubiquitin, suggesting that these SUMO-1 substrates are high 
molecular weight proteins modified with SUMO-1. One potential explanation for the 
appearance of these high molecular weight SUMO-1 conjugates after HDAC inhibition is 
that HDACi is stimulating expression of the SUMO-1 substrate, leading to elevated 
protein levels of the specific target, and therefore a higher percentage of the SUMO-1 
target existing in the SUMO-modified state. If this were the case, HDAC inhibitors 
would be acting through their canonical role by stimulating gene transcription.  
To test if HDAC inhibitors were acting through their canonical role, we assessed 
HDAC inhibitor-mediated SUMOylation after pre-treating with the transcription inhibitor 
ActinoD and the translation inhibitor CHX. In both instances, HDACi-mediated 
SUMOylation occurred, indicating de novo gene transcription and e novo protein 
synthesis were not necessary for stimulation of SUMO-1 conjugates. These data suggest 
that post-translational modification of some component of the SUMOylation process 
gains SUMO conjugation activity in the presence of HDACi. As shown in Table 5, the 
SUMO protease SENP1 was shown to be acetylated. To address the hypothesis of 
whether HDAC inhibitors block SENP1 catalytic activity, therefore leading to the 




shocking of cellular lysate inactivates SENP catalytic activity, so this was used as a 
negative control. Cellular lysates treated with vehicle and the HDAC inhibitor MGCD. 
Unfortunately, no change in SENP catalytic activity was detected. Due to the other 
members of the SCM being identified as targets for lysine acetylation (Table 5) we ran an 
in vitro SUMOylation assay, where we used a chemical acetylation method and 
enzymatic acetylation method to acetylate every member of the SCM excluding the 
substrate, RanGAP1. Chemical acetylation led to a decrease in the activity while 
enzymatic acetylation of the SCM by p300 showed no change in SCM catalytic activity. 
Both of these results were contrary to the initial hypothesis. These results demonstrate 
that the mechanism of HDACi-mediated SUMO-1-ylation remains elusive, but raises the 
intriguing possibility that HDAC inhibition and SUMO-1 gene transfer may yield 
synergistic effects in the treatment of HF.    
 Chapter 3 explored a longtime mystery of the lab, initially focusing on uncovering 
the molecular mechanism by which HDAC inhibitors blunt agonist induced JNK 
phosphorylation. Our lab had previously shown that pre-treatment of NRVMs with class I 
HDAC inhibitors blocked agonist-induced activation of ERK and JNK. Activation of 
ERK was rescued with pre-treatment of ActinoD as well as the protein-tyrosine 
phosphatase inhibitor pervanadate; however these treatments failed to rescue JNK 
phosphorylation in HDACi-treated cells. This led to the hypothesis that HDACi-mediated 
suppression of agonist-induced JNK phosphorylation occurred through a post-
transcriptional/post-translational mechanism. We demonstrated that JNK activation is 
attenuated by HDACi in the presence of overexpressed MAP3K (ASK1) and MAP2K 




reasoned that due to the sheer magnitude of blunting of JNK phosphorylation by HDACi, 
that activation of a gain-of-function chimeric fusion protein MKK7-JNK1 would be 
attenuated in the presence of HDACi. However, the activity of the fusion construct 
measured using phospho-JNK antibody showed no change when treated with TSA or 
MGCD in NRVMs.  
Next, we investigated a clue from a MAPK PCR array previously conducted by 
our lab; where mRNA expression of JIP-1 was elevated several fold with HDACi. Other 
labs had demonstrated suppression of JNK activity when JIP-1 was overexpressed in 
multiple cell types. We validated results from our PCR array, showing elevated levels of 
JIP-1 mRNA with TSA and MGCD. The next intriguing finding was the ability of 
multiple HDAC inhibitors to stimulate expression of not one, but seemingly two isoforms 
of JIP-1. Knockdown of JIP-1 with lentiviruses encoding shRNA targeting JIP-1 as well 
as a paper characterizing the molecular cloning of several JIP-1 isoforms led us to believe 
that these two prominent HDACi-inducible bands were indeed JIP-1 isoforms, which we 
later dubbed JIP-1-SF (short-form) and JIP-1-LF (long-form). Amazingly, when a time 
course experiment was run, tracking the time it takes HDAC inhibitors to suppress JNK 
phosphorylation as well as at what time HDAC inhibitors stimulate expression of these 
two JIP-1 isoforms, blockade of JNK activation almost perfectly correlated with induced 
expression of both JIP-1 isoforms. Adenoviruses encoding JIP-1-SF and JIP-1-LF were 
made in order to test the hypothesis that elevated expression of one or both JIP-1 
isoforms by HDACi blunts agonist-induced JNK activation. However, the results 
depicted in Figure 17 clearly demonstrate that overexpression of JIP-1-SF, JIP-1-LF or 




To confirm these findings, adenoviruses encoding shRNA targeting JIP-1 were made. 
Figure 18 demonstrates the inability of JNK phosphorylation to be rescued in the 
presence of HDACi when both isoforms of JIP-1 are sufficiently knocked down. 
Therefore, the mechanism by which HDACi blunts agonist-induced JNK phosphorylation 
does not involve JIP-1, and thus remains elusive. Many components of the JNK signaling 
pathway are acetylated, which raises the hypothesis that increased acetylation of one or 
more of these constituents is responsible for HDACi-mediated JNK suppression (Table 
7). 
Table 7: Acetylation targets and specific acetyl-lysine residues of proteins implicated in 
the JNK signaling pathway (140, 142). 
 
However, it is apparent that JIP-1 is not functioning via its canonical role in NRVMs. 
The next steps of this project will address this unknown and potentially novel role of 
HDACi-induced JIP-1 in cardiac myocytes. 
 As basic cardiovascular researchers at the CU-Anschutz Medical Campus, we are 




the ability to use this priceless heart tissue to ask questions like: how well did 
pharmacotherapy work in this patient? What are the underlying causes of HF in this 
patient population? Are there molecular signatures in these tissues that will provide 
evidence for use of novel therapeutics? In chapter 4, we described findings of elevated 
HDAC expression and HDAC catalytic activity in a pediatric HF population of single 
ventricle physiology known as Hypoplastic Left Heart Syndrome (Fig. 21-23). Elevated 
HDAC expression and HDAC catalytic activity is consistent with other pre-clinical 
models of HF, yet a translational model of pediatric RV remodeling does not exist. To 
remedy this issue and give the pediatric cardiovascular disease research field a vehicle for 
translating pre-clinical pharmacotherapeutic efficacy to the clinic, we developed a model 
of pediatric RV remodeling that recapitulates much of the cardiac disease phenotype in 
children with single ventricle physiology. This was demonstrated at the physiological 
level using hemodynamics (Fig. 24) as well as at the molecular level by investigating 
token markers of cardiac remodeling and HDAC protein expression and catalytic activity 
(Fig. 25-27). It is our hope that this model will serve as a valuable tool for investigating 
efficacy of potential pharmacotherapeutic compounds for the treatment of pediatric HF, a 
patient population in dire need of an effective drug treatment regimen.  
 Data from these projects add to the ever-accumulating evidence for use of HDAC 
inhibitors in the treatment of various cardiac disorders as well as uncovering new cardiac 
signaling mechanisms. HDAC inhibitor-mediated SUMOylation is consistent with the 
cardioprotective effects of HDAC inhibitors and overexpression of SUMO-1, yet the two 
had never been previously linked. Many researchers before us had shown that 




activation of JNK. We demonstrate that this is not the case for two forms of JIP-1 in 
cardiac myocytes, indicating JIP-1 may be serving a novel role in cardiac signaling. The 
molecular mechanism for HDAC inhibitor’s ability to block PE-induced JNK activation 
remains elusive; however, we may find a novel role for JIP-1 after our RNAseq 
experiment. Though several labs have published on pre-clinical models of neonatal RV 
remodeling, no model had been fully translational or had the ability to run longitudinal 
pharmacological intervention studies. We accepted this challenge and demonstrated that 
protein expression and catalytic activity of several HDAC isoforms are elevated in the 
RVs of human children with single ventricle physiology as well as neonatal rats exposed 
to hypobaric hypoxia. We showed the physiological consequences of rats exposed to 
hypobaric hypoxia accurately mimic the human conditions of RV remodeling and 
pulmonary hypertension via hemodynamics from echocardiographic analysis. We hope 
that this model develops into a useful tool for finding promising therapeutics for the 
treatment of common congenital defects involving pediatric right ventricular remodeling.      
Future Directions 
 The essential next step in the SUMO-1 project is to determine if HDAC inhibition 
stimulates cardiac protein SUMO-1-ylation i  vivo. Outlined in the future directions 
section of chapter 2 is an experimental method to address this hypothesis. Due to the 
finicky nature of detecting SUMOylation by western blot as well as determining the 
proper timing for maximal HDACi pharmacodynamics, this experiment should be run 
carefully. 
Should the hypothesis of HDAC inhibitors stimulating SUMOylation in vivo hold 




hundreds of proteins and acetylation has been implicated in the modification of thousands 
of proteins, many targets with multiple acetylation PTMs. This raises the intriguing 
speculation that efficacy of HDAC inhibition in the setting of HF is at least in part, due to 
the ability of SUMO-1-ylation to be stimulated by HDAC inhibition. Human HF patients 
and mice subjected to LV pressure overload by TAC show significantly decreased levels 
of SUMO-1 (111). In this same study, overexpression of SUMO-1 using rAAV improved 
cardiac function in mice subjected to TAC. Consistent with these results was improved 
efficacy in a porcine model of ischemia/reperfusion (I/R) injury, in which rAAV-SUMO-
1 was delivered via coronary infusion one month after I/R injury. Furthering the concept 
that defective SUMOylation is maladaptive for the heart, elevated levels of SUMO-1, 
dysfunctional hemodynamics and gross malformations of the myocardium were observed 
with cardiac-specific transgenic overexpression of the SUMO protease, SENP2 in the 
mouse myocardium (312). Moreover, elevated expression of SENP1 was shown in failing 
mouse and human hearts, and overexpression of rAAV-SENP1 was sufficient to induce 
dilated Cardiomyopathy in mice (313). Together, these data give credence to effective 
SUMOylation being important for cardiac function, and the intriguing possibility of 
synergistic therapeutic efficacy with SUMO-1 gene therapy and HDAC inhibition. 
With the discovery of hundreds of SUMO-1 targets and thousands of implicated 
acetylation targets, follow on experiments using our newly developed shRNA encoding 
SUMO-1 should be enlightening. One such experiment would be performing RNAseq in 
NRVMs in the absence or presence of shSUMO-1 and/or HDAC inhibition. 
As mentioned in the future directions of chapter 4, the new focus of the JIP-1 




RNAseq experiments will be performed to track changes in gene expression in absence or 
presence of shJIP-1 and/or HDAC inhibition (Fig. 19). An elegant follow on experiment 
to this initial RNAseq experiment would be to add back JIP-1-SF and JIP-1-LF to 
determine if there are divergent roles of these isoforms in cardiac myocytes. Subsequent 
validation of RNAseq results by qPCR would follow from each individual treatment 
group. Specifically designed in this experiment is the first study investigating how 
HDAC inhibitors themselves change NRVM hypertrophic gene expression, measured by 
RNAseq. We know that HDAC inhibitors reverse expression patterns of cardiac 
remodeling in the FGP, but we hypothesize that many other important factors in cardiac 
remodeling that are influenced by HDACs exist.  
Modern pharmacotherapy treatment of HF often relies upon synergistic actions of 
multiple drugs at once, primarily ACEi and –blockers together with aldosterone 
antagonists in some cases. The next steps for experimentation in our pediatric RV 
remodeling model will be investigating the efficacy of ITF2357 and apicidin for 
protection against adverse cardiopulmonary effects. However, we stated that our goal is 
for this model to provide a vehicle for all pharmacotherapeutic discovery, not limited to 
HDAC inhibitors. Milrinone is perhaps the best alternative candidate at this point due to 
emerging evidence for selective efficacy of PDE3i in pediatric vs. adult HF patients. 
Additional studies could test the synergy between HDACi and PDE3i in this model. 
Perspectives 
 Another underlying goal of this dissertation is to provide a research tool for basic 
cardiovascular researchers, giving them: an example of how meticulous empirical 




understanding of how HF patients are currently treated with pharmacotherapy, the 
differences between treatment of pediatric HF and adult HF, understand the specific HF 
patient populations that still have no proven pharmacotherapy, a knowledge foundation 
for some of the many molecular pathways that contribute to cardiac hypertrophy and 
fibrosis, convince basic cardiovascular researchers that HDAC inhibitors are promising 
therapeutic agents for treating HF, and give basic cardiovascular researchers an in vitro 
and in vivo toolkit for answering critical questions without deliberation or re-inventing 
the wheel. 
It is no secret among academic medical centers and basic research facilities 
around the country that scarce and increasingly competitive funding lines for grants are 
not improving quickly. With this in mind, our lab has developed an economical method 
for validation of genetic knockdown with shRNA. This will be extensively discussed in 
appendices I and II, but the highlights are: obtaining validated pLKO.1 shRNA plasmids 
for a very reasonable price for production of lentiviruses, validating knockdown of 
specific targets by qPCR or immunoblotting, inserting these sequences into adenoviruses 
for subsequent functional studies in cultured cardiac myocytes or using these sequences 
as a template for transfectable siRNAs. Another economical method that our lab has yet 
to develop is using recombinant adeno-associated viruses (rAAV), of which tropism is 
highly selective for cardiac myocytes, prior to developing or starting a new knockout 
mouse colony. Arguments can be made for which rAAV serotype to use in these studies 
and at what time points in which to use them, but several basic cardiovascular labs have 
demonstrated efficacy for cardiac-specific gene expression using rAAV-1(314) and 




(i.e. through tail-vein) in wild type mice using rAAV-GFP or a previously validated 
rAAV-shRNA as a control alongside an rAAV delivering the genetic material of interest, 
monitor the mice for one month, harvest the target organ (in our case, the heart) and run 
the necessary qPCR or immunoblot to verify efficacy and dose of the rAAV. The 
advantages are: efficacy for shRNA encoded rAAV can be seen in as little as one month 
after dosage; limi ting systemic effects with organ targeted rAAV in wild type mice; no 
need to crossbreed floxed mice with tissue-specific Cre mice, saving time-to-experiment 
and cutting down on genotyping; initial experimental observations can be determined 
relatively quickly; justification for using knockout mice by yielding promising 
preliminary data; and as another validation source that the observed phenotypes and/or 
molecular actions are real. Some disadvantages are: the different abilities of rAAV 
serotypes to cross the blood vessel barrier, pre-determining the preferred method of 
rAAV delivery; titration of the correct doses needed for optimal Tg-expression or genetic 
knockdown may be finicky; making rAAV is not trivial, meriting the need of an AAV 
expert in the lab. This is a good case for the future use of AAV as an economical time-
saving method for in vivo animal studies and as another source of validation should the 
subsequent follow-up experiments require knockout animals.  
Reproducibility in basic research has also been a hot topic as of late. A fortunate 
reality of basic cardiovascular research is that the gold standard method for studying 
cardiac myocyte and cardiac fibroblast signaling utilizes primary cells, leaving little room 
for unexpected manipulations, i.e. molecular and morphological changes in passaged 
cells that may have been split 10-100 times over and changed significantly from 




to be rendered not reproducible. While our lab uses PE as an 1- drenergic receptor 
agonist at a minimum effective concentration of 10 μM, it is not uncommon to find 
studies in the literature using a concentration 10x we use in our lab. At 10x the minimum 
effective concentration of any pharmacological treatment, it would not be surprising that 
an observed response may not be occurring through the intended canonical signaling 
pathway, or the results of the intended manipulation of a signaling pathway are 
compounded by other peripheral events as well. Careful consideration should be taken 
when trying to reproduce these types of results.  
With the exception of Ivabradine and LCZ696, drug development in the realm of 
cardiovascular disease has been abysmal for the past 25 years. There are several reasons 
for this: HF is a very complex disease; not everyone is going to benefit from a specific 
treatment; patient selection is crucial, varies widely between clinical trials and can be 
subjective; HF trials need to be very large, take several years and several sites to run, and 
are incredibly expensive; and many of the latest failures have targeted very specific 
enzymes implicated in few cellular signaling pathways. Recent drug candidates that 
failed to meet primary and/or secondary endpoints in Phase III clinical trials for treatment 
of acute HF include: tezosentan (non-selective ETA and ETB antagonist) (316), 
levosimendan (binds to cTnC and increases Ca2+ sensitivity) (317), tolvaptan 
(competitive vasopressin receptor 2 antagonist) (318), rolofylline (diuretic that acts as a 
selective adenosine A1 receptor antagonist) (319), and the very recent failure of Mydicar 
(rAAV1-mediated delivery of SERCA2a) in the calcium up-regulation by percutaneous 
administration of gene therapy in cardiac disease phase 2b (CUPID2) trial to meet its 




selectively target specific enzymes or receptors (i.e. ACEi, -blockers, ARBs); however 
we may have discovered the majority of the low-hanging fruit using this approach. 
Perhaps we need to broaden our drug candidate armamentarium by developing candidates 
that have wide range effects on many cellular processes, or repurposing “dirty” drugs for 
diseases that these compounds were not applied to in the past. Our cells have many 
checks and balances in the molecular circuitry to circumvent an overactive, faulty or 
pharmacologically manipulated cellular signaling pathway. Perhaps we are being too 
focused in our drug development effort and need to target enzymes involved in many 
cellular processes, of which, pharmacologic manipulation has few or very tolerable side 
effects. 
One fortunate observation from the CUPID trial data was the ability of high doses 
of Mydicar to meet its primary safety and efficacy endpoints at 6 months versus placebo. 
These observations are at least encouraging for the future of gene therapy, even with the 
failure of Mydicar to successfully meet its study endpoints. Pre-clinical data from one of 
the major CUPID investigator’s lab indicates that gene therapy using rAAV-SUMO-1 
demonstrated remarkable efficacy in several models of HF, and has been highlighted in 
previous chapters. As mentioned previously, SUMO-1 has the ability to modify hundreds 
of different proteins implicated in virtually every cellular signaling pathway, tweaking 
the function of each individual target. Perhaps system-wide, tolerable changes in global 
cellular signaling using SUMO-1 or other small protein modifiers is the gate-keeper for 
the next generation of gene therapeutics.  
Approximately 98.5% of the human genome is not translated into protein (321). 




PTM is an ancient cellular mechanism allowing functional changes in a target protein 
without the need of synthesizing more of that target protein, or by synthesizing an 
entirely different protein needed for the specific spatiotemporal response to a given 
cellular stimuli. Another potential gate-keeper for next-gen therapeutics may be 
proteome-wide changes in chemical modifications like acetylation. However, there are 
many other acyl modifying networks like lysine-crotonylation (322) and lysine-
succinylation (323), and insight into the ability to pharmacologically manipulate these 
acyl-signaling networks is still in its infancy. These PTMs appear to be highly abundant 
in the mitochondria and regulated by metabolism. The heart is a highly metabolic organ 
and it will be interesting to see how research progresses shedding light on the roles of 
these acyl modifications in the heart as well. 
Now that we have discovered that pharmacological manipulation of one PTM 
network (acetylation) gives rise to another PTM network (SUMOylation), the potential 
complexity of signaling crosstalk as well as possibilities for multi-pronged approaches to 
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A1. Production of Lentiviruses 
After much deliberation, protocol comparison, and empirical experimentation, we have a 
(relatively) easy and cheap method to making lentiviruses encoding shRNAs. Follow this 
protocol step by step and you should obtain great knockdown of your gene of interest! 
This protocol was adapted from the CU Boulder Functional Genomics Core and Cold 
Spring Harbor’s methods. The Functional Genomics Core has purchased the entire library 
of shRNA constructs from Sigma-Aldrich, and glycerol stocks of shRNA constructs are 
between $20-$25. Noteμ the library includes genes from humans and mice. If you’re 
looking to knockdown a rat gene, make sure the short-hairpin sequences overlay close to 
100%. 
A2. Determining your shRNA construct: 
1) When choosing your shRNA construct, go to Sigma’s websiteμ 
www.sigmaalrich.com.  
2) Enter the abbreviation of the gene you wish to knockdown (i.e. tp53). 
3) The gene will show up with the gene abbreviation, full name, synonyms, species, 
summary, and products. Under the products options, click shRNA. 
4) Usually they offer three different products of shRNA: MISSION shRNA Bacterial 
Glycerol Stock, MISSION shRNA Plasmid DNA, MISSION shRNA Lentiviral 
Transduction Particles. Click on the blue PRICING button next to MISSION 
shRNA Plasmid DNA according to which species of cell you are using (mouse 




5) A tab will pop up with several products that have a TRC Number. These are your 
lentiviral construct sequences. First: pick a sequence that has an orange box with 
VALIDATED under the Product Details. Second: determine if you want your 
miRNA sequence to target the coding sequence (CDS) or the 3’UTR of your gene 
of interest. Third: choose a sequence that has a very high Mean KnockDown 
Level, ideally over 0.λ0 or λ0%. Fourthμ if you’re looking to knock down a rat 
gene, blast the shRNA sequence of the mouse shRNA sequence against the rat 
gene of interest. Every sequence starts with CCGG; after this sequence, the short 
hair sequence is the next ~21 nucleotides until you reach the middle stem-loop 
sequence of CTCGAG. Compare these 21 nucleotides between species and see if 
they match up. 
CCGGGACCTCAGTGACAACGCATTTCTCGAGAAATGCGTTGTCACTGAGGTCTTT
TTG 
6) Once you’ve chosen your desired sequence, copy the TRC number (i.e. 
TRCN0000106238, sequence shown above for the mouse RanGAP1 shRNA) and 
then go to the CU Boulder Functional Genomics website: 
http://functionalgenomics.colorado.edu/. 
7) Click on the Order Form link on the Functional Genomics website and fill out the 
order form with all of the required information. For Quantity, choose 1, and for 
Format, choose glycerol stock. Each glycerol stock will be between $20-$25.  
8) Glycerol stock will arrive either the next day or in 2-3 days, depending on what 
shipping you choose. We do 2-3 day shipping now because it’s way cheaper. 




resistant. Grow up a large, overnight bacterial solution and run a midi or maxi 
prep the next day.  
9) Before you start seeding your cells and planning how much lentivirus to produce, 
always make sure that you have enough of your packaging and envelope 
plasmids. psPAX2 is your packaging plasmid and pMD2.G is your envelope 
plasmid. The rest of the genetic material needed to make viable virus is encoded 
in your pLKO.1 shRNA plasmid. When you are making virus, you will need 10x 
more psPAX2 than pMD2.G, so calculate how much packaging plasmid you will 
need several days before you begin your transfection. You may need to grow up 
more psPAX2. 
10) The cells used to produce the lentivirus are L293s that we obtained from Dr. 
Kunhua Song. These cells can be slightly finicky, so here are some useful tips. 
Use DMEM/PSG/10% FBS for the media. When you thaw them from a cryovial, 
it will take them around 48 hours to fully recover and look healthy. After 48 
hours, the cells should be ~70-80% confluent and ready to be split. When you 
split them, never split them more than 1:10. If they are split to thin they do not 
grow very well. All of our frozen cells are around passage 5. Once the cells reach 
passage 15, discard them because their ability to produce potent virus diminishes.  
11) Day 1: Plate around 2x106 L293 cells in 10 cm dishes and incubate overnight at 
37°C and 5% CO2.  
12) Day 2: Cells should be around 70% confluent at the time of transfection. Also, the 
cells should be transfected in the late afternoon because the transfection mix 




hours prior to transfection by adding 6.4 mLs of 10% FBS/DMEM/PSG to the 
cells. Note: the ratio of packaging plasmid/envelope plasmid/shRNA plasmid are 
the amounts from the Broad Institute’s protocol and are different than Kunhua’s 
amounts. I have tried both and the plasmid amounts from the Broad’s protocol 
have yielded better virus for me. For each transfection, you will need: 
a. λ g packaging plasmid, psPAX2 (CU172) 
b. 0.λ g envelope plasmid, pMD2.G (CU171) 
c. λ g shRNA plasmid, pLKO.1 
d. Prior to making a master mix, I dilute each plasmid to 100ng/ L. 
e. Follow these steps when making your master mix: 
i. Combine λ0 L psPAX2 with λ L pMD2.G per plate, adding an 
additional plate or two to make up for pipettor error. 
ii.  Add λλ L of packaging vector mix, λ0 L of desired pLKO.1 
plasmid, and 611 L of Serum/PSG free DMEM (per transfection) 
into a 15mL conical. 
iii.  At the same time, add 57 L of polyethyleneimine (PEI) to 743 L 
of Serum/PSG free DMEM (per transfection) into a separate 15mL 
conical.  
iv. Wait 5 minutes. 
v. Combine contents of your conicals, and wait 15 minutes.  
vi. Add 1.6mL of transfection cocktail to each 10cm dish. 
13) Day 3: In the morning, change the media to remove the transfection reagent. 




14) Day 4: No action is necessary on Day 4. 
15) Day 5: Harvest media from cells and transfer to a 50mL conical. Filter the viral 
media through a 0.45 m filter to remove cells/cell debris. Aliquot and store at -
80°C until use. 
A3. Lentiviral Transduction Protocol 
Different shRNA sequences targeting the same gene have been demonstrated to have 
varying effects. You will not know exactly how well your gene is knocked down until 
you try it in a specific cell type for a specific amount of time. Depending on the gene, we 
have achieved close to 100% knockdown in NRVMs, NRVFs, and C2C12s. The protocol 
below has been working for us as of late.  
1) Use p60 tissue culture plates to minimize the amount of lentiviral media needed. 
For NRVMs: 
2) Monday: NRVM prep occurs. 
3) Tuesday morning:  
a. Wash 1x in Serum/PSG free DMEM.  
b. Add 3mL of Nutridoma/PSG/DMEM to each uninfected plate. Also, add 
3 L of polybrene [stock 10mg/mL] to each uninfected plate. 
c. Add 3-4mL of lentiviral media to each plate. Also, add 3 L of polybrene 
[stock 10mg/mL] to each uninfected plate. Polybrene is a cationic polymer 
used to increase efficiency of infection of certain cells with virus in 
culture. 





5) For best knockdown, wait until Friday afternoon or Saturday morning to lyse the 
cells. 
6) Run SDS-PAGE or qPCR to verify knockdown, as shown in Figure 28. 
 
Fig. 28. Verification of knockdown in C2C12 mouse myoblasts. Three digit numbers 
before lenti refer to the last three numbers of the TRC# from the specific pLKO.1 
plasmid. (A) Two independent tissue culture dishes were infected with shControl 
lentivirus or lentivirus encoding shRanGAP1. (B) Two independent tissue culture dishes 
were infected with shControl lentivirus or increasing amounts of lentivirus encoding 
shRanBP2. Due to the robust knockdown efficiency, these shRNA sequences are good 
candidates for insertion into adenovirus.  
 
A4. Making PEI Reagent 
1) Polyethyleneimine, linear from Polysciences, Inc. Cat#23966, MW: ~25,000. 2 
grams runs for $103. If the cell type of interest is easily transfectable, the lab may 




2) Heat Milli-Q water to 65-80°C; add 200mg of PEI powder to 200mL water. Stir 
vigorously with a stir bar. START THIS FIRST THING IN THE MORNING; IT 
MAY TAKE HOURS TO GO INTO SOLUTION. 
3) After all of the PEI is dissolved, continue stirring vigorously for 10 minutes. 
4) Once you see no visible solids, cover your beaker with parafilm and cool the 
solution to room temperature on your benchtop. Once solution is at room 
temperature, pH to 7.05 with HCl. 
5) Filter through 0.22 m membrane. YOU HAVE TO DO THIS!!! The presence of 
undissolved PEI particles will precipitate DNA, and cannot be transported into 
cells. 
6) Aliquot into 1mL aliquots and store at -80°C. Once thawed the tube should be 
kept at 4°C. Date the top of the tube because it is only good for a month. 
7) PEI has worked best when we’ve used it at a 3μ1, PEI: DNA ratio. It works in 
Cos7, L293, 293A, C2C12, and NRVMs. 
 
APPENDIX B 
B1. Production of Adenoviruses 
As previously mentioned in chapter 3, this section will describe how to translate the 




B2. Designing Your shRNA Oligonucleotides 
As alluded to above, the sequence from Sigma’s website contains a starter sequence 
(always CCGG), ~21 nucleotide RNAi sequence, stem loop (always CTCGAG) and end 
sequence. Notice that both RNAi segments are perfect complements of one another when 




JIP-1 TRCN0000012602:  
CCGGGTGTCTGAAGATTCCACCAAACTCGAGTTTGGTGGAATCTTCAGACACT
TTTT 
1. After validating these constructs in lentivirus, these same RNAi sequences and 
stem-loop can be modified for entry into the pAd-BLOCK-iT DEST system for 
shRNA encoding adenoviruses.  
2. Using JIP-1 600 as an example, the sequence needs to be slightly modified for 
ligation into the entry vector, pENTR-U6. pENTR-U6 is a linearized plasmid with 
4 nucleotide overhangs on each end. You will need to remove the start and end 
nucleotides from JIP-1 600 and add the necessary 4 nucleotides for ligation into 
pENTR-U6. Example is shown below: 
5’=>3’ Top strand oligoμ 
CACCCACGCTGAATAATAACTCTTTCTCGAGAAAGAGTTATTATTCAG
CGTG 






3. Notice the two RNAi and stem-loop sequences match perfectly with JIP-1 600 
above, as well as the top strand and bottom strand being perfectly identical to one 
another, with the exception of the end sequences. If you fold both sequences upon 
each other, there will be perfect complementarity and a 4 nucleotide overhang on 
each end. This is essential for entry into pENTR-U6.  
4. Once your primers are designed, carefully follow the pAd-BLOCK-iT DEST 
manufacturers’ instructions and you will be on your way to effective genetic 
knockdown tools in adenovirus! 
 
